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ABSTRACT 
  The pursuit of efficient and safe alternatives to improve health and 
treat physical/mental illness has found in plant extracts a potential source of 
bioactive compounds such as polyphenols. The work presented within this 
thesis aimed to investigate the changes in the plant extract after ingestion, 
identify the remaining polyphenols and phase II conjugates, and to finally 
test their possible biological activity in in vitro assays.  
  German chamomile (GC) was used as experimental case which was 
treated with a multiple-enzyme hydrolysis to mimic the process most likely to 
occur in the gastrointestinal tract. This methodology was previously used in 
five different fruit matrices and it was successfully applied to plant-based 
materials. It was possible to identify and quantify a series of compounds 
before and after treatment by LC-ESI/MS, and these results were compared 
with data found in the literature. In addition, it was found that differences in 
sample preparation and a suitable organic solvent for liquid-liquid extraction 
had an important impact in the quantification of these compounds.  
  The transformation of polyphenols after the phase II metabolism was 
also investigated. For this purpose, hesperetin aglycone was used in the 
laboratory to produce the main monosulfate commonly found in urine 
samples. For the first time, p-nitropheyl sulfate (PNS) was used as co-
cofactor in the biological sulfonation of polyphenols which enhanced the 
transformation to hesperetin-3'-O-sulfate (Hp3'SO4). Indeed, it was the first 
time that Hp3'SO4 was quantified in urine samples after orange juice 
consumption using a true standard. 
  Finally, the anti-inflammatory activity of tested plant extracts and their 
main polyphenols was assessed by measuring their inhibitory activity against 
recombinant human COX-2. An enzyme immunoassay (EIA) and in vitro-LC-
MS methodologies were used for this purpose. Consistent COX-2 inhibition 
was found for green tea (GT) and its two major polyphenols, 
epigallocatechin gallate (EGCG) and epigallocatechin (EGC) which showed 
inhibition in a concentration dependence manner. On the other hand, various 
polyphenols and plant extracts also presented COX-2 inhibition, but did not 
show concentration dependence.    
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CHAPTER 1 Literature review  
 
1.1 Plant extracts and their bioactive compounds 
Plant extracts have been used as remedies to ease common 
afflictions for centuries and their popularity in Europe is increasing (Garcia-
Alvarez et al., 2014). Plants are used in different types of products such as 
food supplements, ointments and herbal medicines amongst others. The 
World Health Organisation (WHO) has listed them as part of the 
traditional/complementary/alternative medicine and included them as herbal 
medicine (WHO, 2002). Their importance has been addressed in the latest 
report by the World Health Organization (WHO, 2014), as their economic 
impact is growing in developing and industrialised countries. Information 
about their health benefits has been reported and it has been mostly 
attributed to different phytochemicals, in particular polyphenols (Crozier et al., 
2009; Chow and Hakim, 2011; Williamson et al., 2011)  
Polyphenols are plant secondary metabolites, widely found in fruits, 
vegetables, cereals and different beverages (Pandey and Rizvi, 2009). They 
contribute to general maintenance of the plant and are allocated in different 
cellular and subcellular levels in situ. It has been reported that the 
polyphenol content in plants can be affected by several factors, such as 
variety, growing environment, temperature, interaction with other 
polyphenols and many others (D’Archivio et al., 2010). For instance, Alfaro 
et al. (2013) conducted a five year study to determine the impact of growing 
season on murtilla fruits (Ugni molinae Turcz) and found that the plant is 
affected by high rainfall and number of frosts during the season, increasing 
its polyphenol content. As well, Eid et al. (2013) tested the effect of cultivar 
and ripening on polyphenol content of dates. They found that the 
concentration of polyphenols was higher in unripe dates (kimri stage) than 
mature stages (e.g. rutab or tamr) and the cultivar Ajwa presented higher 
polyphenol content at the khalal stage than Barni and Khalas cultivars.  
 Different groups of polyphenols will be present in the plant and they 
are classified according to their number of phenol rings and the structure 
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that it binds them. They are: phenolic acids, flavonoids, stilbenes and lignans 
(see Table 1.1) (Manach et al., 2004).  
Table ‎1.1 (Poly)phenol classification and example(s) for each category. 
Classification Chemical structure 
Phenolic acids 
Gallic acid  
(benzoic acid derivative) 
 
Coumaric acid  
(cinnamic acid derivative) 
 
 
Flavonoids 
Kaempferol 
(flavonol) 
 
 
Epicatechin 
(flavanol) 
 
 
Stilbenes 
Resveratrol 
 
Lignans 
Secoisolariciresinol 
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  Flavonoids are the most abundant polyphenols in the plant kingdom 
and their main subclasses are flavonols, flavones, flavan-3-ols, 
anthocyanidins, flavanones and isoflavones. There are other minor 
subclasses which are dihydroflavonols, flavan-3,4-diols, coumarins, 
chalcones, dihydrochalcones and aurones (Crozier et al., 2009). A 
combination of these subclasses can be found in a single plant. For instance, 
German chamomile (Matricaria recutita) is used to ease skin affections and 
it contains flavones (e.g. apigenin-7-O-glucoside), flavonols (e.g. quercetin), 
flavanones (e.g. naringenin) and coumarins (e.g. umbelliferone) (Singh et al., 
2011). Green tea (Camellia sinensis) is highly sought for its potential health 
benefits against cardiovascular diseases, cancer, osteoporosis and others, 
and it is a rich source of flavan-3-ols such as epicatechin and its esterified 
form epigallocatechin gallate. It also contains flavonols such as quercetin, 
kaempferol and myricetin (Crozier et al., 2009). Indeed, other plant extracts, 
like ginseng and ginkgo, contain different compounds of notable interest. 
Ginseng (the roots of Panax ginseng) is commonly used in Traditional 
Chinese Medicine and it contains different compounds such as fatty acids, 
flavonoids, polysaccharide, saponins and others. It is believed that a class of 
saponins, known as ginsenosides (see Figure 1.1), are the major bioactive 
compounds of the plant and these are of major scientific relevance (Wang et 
al., 2012a).  
 
Figure ‎1.1 Ginsenosides examples. Ginsenoside Re is a natural 
glycoside and protopanaxatriol is a cyclic alcohol. Glc= glucose, Rha= 
rhamnose.  
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 Ginkgo (Ginkgo biloba) is also widely used in Traditional Chinese 
Medicine and its commercially-available extracts contain different flavonoids 
(e.g. quercetin, isorhamnetin, kaempferol and their glycoside derivatives) 
and various terpene lactones (Dew et al., 2014). The terpene lactones are 
divided into diterpenes (gingkgolides) and sesquiterpenes (bilobalide) (see 
Figure 1.2 ), and are reported to help the treatment against mental diseases 
like dementia (Solfrizzi and Panza, 2015).   
 
Figure ‎1.2 Ginkgolide examples. Ginkgolide A and bilobalide are 
terpene lactones.  
  Identification of the main compounds in plants is the first step to 
provide a profile of the possible active analytes. The composition is the key 
to understand the plant and it provides evidence to support further analyses. 
For example, German chamomile has been analysed by different research 
groups focusing on its content of apigenin aglycone and its derivatives 
(Švehlıḱová et al., 2004; Srivastava and Gupta, 2009; Avula et al., 2013), but 
few other papers have searched for other compounds such as umbelliferone, 
luteolin, ferulic acid hexoside and others (Lin and Harnly, 2012; Guimaraes 
et al., 2013; Matic et al., 2013). The quest for a simple methodology that 
provides sensitivity and selectivity to identify and quantify a wider range of 
plant polyphenols is still ongoing.  
 
1.2 Metabolism of plant polyphenols 
  Flavonoids occur in plants in the form of esters, glycosides or 
polymers that cannot be absorbed in their native form. After plant extracts 
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have been consumed, flavonoids pass through the digestive system and 
undergo a series of reactions to be absorbed, metabolised and further 
excreted (O’Leary et al., 2001; Manach et al., 2004). The first step of 
metabolism is deglycosylation of flavonoid glycosides to release their 
aglycone form (see Figure 2.1) (Aherne and O’Brien, 2002). This process 
can occur in the plant itself, in the gastrointestinal mucosa, or in the colonic 
microflora which release simple aromatic acids during this process. Non-
enzymatic deglycosylation does not happen in humans (Scalbert and 
Williamson, 2000).  
  Phase II metabolism is characterised by the conjugation of aglycones 
to yield glucuronidated, sulfated and methylated forms. These processes 
take place in the cells of the small intestine and liver, but sulfation mainly 
takes place in the liver (Dueñas et al., 2011). A concise diagram of these 
pathways can be seen in Figure 1.3. 
  It has been suggested that conjugation will vary according to the 
nature of food and dose ingested. Indeed, the balance between sulfation and 
glucuronidation may be affected by type, gender and lack/abundance of food, 
as well as the composition and competence of each individual’s gut 
microflora (Manach et al., 2004; Crozier et al., 2009). Conjugation reactions 
increase the solubility of the flavonoids which lead them to further excretion. 
Large conjugated forms are more likely to be eliminated in the bile while 
smaller conjugated forms are excreted in urine (O’Leary et al., 2001; 
Manach et al., 2004). 
1.2.1 How polyphenol conjugates are identified and quantified? 
  The conjugated forms are chemically distinct from their aglycones and 
are more likely to have different physiological activities (Kroon et al., 2004). 
Human studies investigating the pharmacokinetic parameters and biological 
effects of conjugate forms normally collect plasma and urine samples to 
perform the analysis. However, if plasma is not available, urine can be used 
to determine the degree of absorption of the target compounds.   
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Figure ‎1.3 Diagram of phase II metabolism routes in humans. 
Conjugated forms: GlucA=glucuronidated, Sulf=sulfated and 
Meth=methylated.    
  Research on polyphenol conjugates has focused on the identification 
of the main conjugated forms that appear in vivo for which various analytical 
techniques have been developed. The most common techniques are liquid 
chromatography (LC), gas chromatography (GC), liquid chromatography-
mass spectrometry (LC-MS) and immunoassays (e.g. ELISA) (Wilkinson et 
al., 2002). The main advantages and disadvantages for each technique, e.g. 
sensitivity, multi-analyte detection, sample preparation, cost of 
preparation/reagents/equipment among others, are critical depending on the 
analyte and its chemical specifications. For instance, analysis of soy foods 
does not require high sensitivity techniques as the isoflavonoid analytes are 
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present at significant concentrations. Thus, HPLC-DAD is a suitable 
technique to identify and quantify the major soy metabolites (Wilkinson et al., 
2002).  
  Currently, the most used technique to determine the appearance of 
conjugated flavonoids after food ingestion is enzymatic hydrolysis. The 
quantification is performed measuring the aglycone forms for each 
metabolite by LC or LC-MS. However, it has been shown that not all 
conjugates are good substrates for these commercial enzymes which could 
likely underestimate the conjugates quantification (Farrell et al., 2011; Saha 
et al., 2012). Furthermore, the synthesis of true standards of the conjugate 
forms has become an important research field which will help to determine 
the appropriate concentration of flavonoid conjugates to use in in vitro 
assays. For example, hesperidin is a flavanone found in citrus that after 
deglycosylation (first metabolism) is transformed into hesperetin (aglycone 
form). Hesperetin conjugates (e.g. hesperetin-3'-O-glucuronide) have been 
identified in urine samples after orange juice consumption (Brett et al., 2009; 
Bredsdorff et al., 2010; Brand et al., 2010; Pereira-Caro et al., 2014), but the 
positive quantification of hesperetin sulfate has relied on LC-MS2 and NMR 
identification. So far, these publications have agreed that hesperetin-3'-O-
sulfate is the main monosulfate found in urine after orange juice 
consumption, but none has used a true standard for its identification or 
quantification.  
1.2.2 Sulfate polyphenols and their occurrence in humans.  
  Sulfation is an important pathway in the transformation of polyphenols, 
hormones, drugs, chemical carcinogens and others. The enzymes in charge 
of this reaction are known as sulfotransferases (SULTs) and are located in 
the Golgi apparatus and in the cytosol of cells (Gamage et al., 2006). The 
cytosolic SULTs catalyse the sulfation reaction where the activate sulfate, 
adenoside 3'-phosphate 5'-phosphosulfate (PAPS) donates a sulfite group 
(SO3
2-) to a compound with a hydroxyl or amino group to form a sulfate or 
sulfamate ester (see Figure  1.4).   
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Figure ‎1.4 Sulfation reaction catalised by SULTs (sulfotransferase) 
using the universal donor PAPS with the example of quercetin to 
quercetin-3-O-sulfate (Q3SO4).  
   Five distinct SULT families have been identified in mammals, but only 
three families and thirteen distinct members have been characterised in 
humans. These are: SULT1 – A1,A2,A3,A4,B1,C2,C4,E1; SULT2 – A1 and 
B1 and SULT4 – A1. Gamage et al. (2006) have published detailed 
information for each family and their function in the metabolism of 
xenobiotics (e.g. polyphenols).  
  Miksits et al. (2005) investigated the effect of different sources of 
SULTs (human liver cytosol and recombinant sulfotransferase isoforms) on 
the formation of resveratrol sulfate and they found similar synthesis rates 
between SULT1A1 and liver cytosol and suggested the conjugation of 
resveratrol-3-O-sulfate, resveratrol-3,4'-O-disulfate and resveratrol-4'-O-
sulfate. The conjugation of hesperetin was reported by Brand et al. (2010) 
who compared individual sulfotransferases and rat and human tissue 
samples. They found that hesperetin was mainly sulfonated in the positions 
7 and 3' and SULT1A1 was inhibited by substrate at concentrations > 0.15 
µM. They also found that conjugation by the human cytosolic fractions (small 
intestine and liver) showed affinity to sulfonation of position 3'. Hesperetin 
was not conjugated by rat small intestinal cytosol, but hesperetin-7-O-sulfate 
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was formed by rat liver cytosol which contains SULT1C4, a form not 
detected in human liver. 
   In the sulfation reaction PAPS is commonly used as sulfate donor, but 
there are other compounds that have been reported to be donors such as p-
nitrophenyl sulfate. Koizumi et al. (1990); (1991) reported the successful 
sulfonation of quercetin, phenolic acids (e.g. gallic acid) and other 
polyphenols using p-nitrophenyl sulfate (PNS) as sulfate donor instead of 
PAPS. They discovered that a novel type of sulfotransferase from the human 
intestinal bacterium (Eubacterium A-44) catalysed the transfer of the sulfate 
group using a phenol sulfate esters and not PAPS. In fact, it was until 
Tyapochkin et al. (2009) proposed a bypass mechanism between PAPS and 
PNS that PNS was considered not only a sulfate donor, but a co-cofactor of 
the sulfonation reaction. So far, there are not published articles that report 
experimental data of the combined mechanism PAPS-PNS for the biological 
sulfonation of polyphenols.   
1.2.3 Polyphenol conjugates and their biological activity   
   It is known that polyphenols are present in foods as glycosides. 
Following ingestion, glycosides are deconjugated to their aglycone form and 
are further metabolised to phase II metabolites (see Figure 1.3) which can 
be found in biological fluids (e.g. blood and urine). Scientific publications 
have proposed that flavonoid conjugation and deconjugation play an 
important role in their biological activity and affect the absorption and 
bioavailability of the conjugates (Williamson et al., 2005; Beekmann et al., 
2012). 
  Williamson et al. (2005) published an early review which compiled 
information about the activity of flavonoid aglycones and their conjugates, 
and hypothesised that flavonoids conjugates retain some biologically active 
properties from their aglycones. Firstly, they reported that quercetin 
glucuronides inhibited xanthine oxidase according to the position of 
substitution (e.g. 4' > 3') and suggested that the inhibition depended on the 
position of the substitution and less in the type of substitution. In the case of 
EGCG, EGC and their glucuronides they described that aglycones and 
conjugates inhibited the release of arachidonic acid in HT-29 human colon 
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cancer cells at different degrees. Some glucuronides were less effective 
than aglycones (e.g. EGC > EGC-3'-O-β-glucuronide, EGCG > EGCG-7-O-
β-D-glucuronide) and EGCG-3'-, 3''- and 4''-O-β-D-glucuronides acted the 
same as EGCG. They reported that hesperetin glucuronides protected (25%) 
against UV-A-induced necrotic cells death in human foreskin derived 
fibroblast (FEK4), but hesperetin aglycone did not have effect. On the other 
hand, using in vitro mouse brain endothelial cell models (bEND5 and RBE4), 
hesperetin and naringenin aglycones passed more freely the transverse 
blood brain barrier than their conjugates. They presented information about 
the activity of other flavonoids such as isoflavones and baicalin.  
  A recent review, published by Beekmann et al. (2012) presented the 
effects of various flavonoids (e.g. EC, kaempferol, luteolin, quercetin and 
others) on different biological endpoints such as oxidative stress, cell 
adhesion, COX-2 transcription/activity and angiogenesis. They pointed that 
several general factors influence the effects of flavonoids conjugates on in 
vitro and in vivo assays. For instance, they suggested that conjugation can 
affect polarity and size of the compounds which will affect protein binding, 
cellular uptake and further affect the availability of the flavonoids to cells and 
tissues. Additionally, they reported that flavonoid conjugates can be taken up 
and then metabolised by various cell types during incubation of in vitro 
assays, but it is not usually specified as most reports do not characterise 
samples at the end of the incubation period. They also reported that 
flavonoids, due to their size and polarity, need to rely on active transport or 
deconjugation to pass cell membranes and act within cells. However, this 
phenomenon depends on the type of model system, as it has been reported 
that quercetin glucuronidated needs to be deconjugated before uptake into 
HUVEC cells, but it can be taken up without deconjugation by HepG2 cells. 
In addition, they also supported that the position of conjugation plays a more 
important role in the activity of the conjugate than the type of conjugation, 
and advised to take into account relevant concentrations, incubation times 
and to monitor the metabolic fate of the flavonoids in the chosen system to 
avoid misleading results. Finally, Del Rio et al. (2012) have published a 
comprehensive overview of flavonoids which provides information about 
their classification, bioavailability, in vitro biological activity, outcomes from in 
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vivo studies and their possible mechanism of action on chronic diseases 
such as cancer and neurodegenerative diseases.  
  Overall, these publications have made clear that information available 
for the biological activity of flavonoids conjugates is still insufficient, and it is 
necessary to perform improved in vitro assays and design better in vivo 
studies to obtain relevant data about the interactions of flavonoid conjugates 
with the human body and pathological disorders.  
 
1.3 Polyphenols and their effect on inflammation 
1.3.1 Inflammation: chronic or acute? 
  Inflammation is a complex reaction that it is often a response resulting 
from bacterial infection, injury, trauma, or ultraviolet light irradiation. This can 
be beneficial (restoration of homeostasis) or harmful (damage to cells and 
tissues) (Huang et al., 2004). Inflammation is generally divided into acute 
and chronic. The first is believed to be a defence mechanism and facilitate 
wound repair. In contrast, chronic inflammation is the result of 
overproduction of pro-inflammatory enzymes and is mostly detrimental. 
Chronic inflammation is associated with immunopathological changes that 
play an important role in the development of degenerative diseases such as 
cancer, arthritis, atherosclerosis, diabetes, Alzheimer’s, asthma and others 
(Huang et al., 2004; Evans et al., 2006).  
1.3.2 Cyclooxygenase 2 and its role in health disorders 
  Cyclooxygenases are formally known as prostaglandin endoperoxide 
H synthases and they catalyse the oxidative reaction of essential fatty acids 
such as arachidonic acid and eicosapentaenoic acid for the biosynthesis of 
prostaglandins (PG). There are three isoforms: COX-1 is usually expressed 
in cells and tissues, COX-2 leads to the formation of PG and the less studied 
COX-3, which is expressed in specific areas including brain and spinal cord 
(Smith, 2007; Cerella et al., 2010). 
  COX-1 and COX-2 have similar tertiary structures and perform 
essentially the same catalytic reaction; both convert arachidonic acid to 
- 12 - 
 
 
PGH2 which it is further transformed into a variety of prostaglandins or 
thromboxane A2 (see Figure  1.5).  
 
Figure ‎1.5 The action of COX on the arachidonic acid (AA) pathway. AA 
is released and metabolised by COX-1 or COX-2 into prostaglandin G2 
and further into prostaglandin H2. Furthermore, prostaglandin H2 is 
converted to prostaglandins and thromboxanes by specific terminal 
synthases. The cyclopentenones (PGJ2 and 15d-PGJ2) are non-
enzymatic degradation products of PGD2. PG = prostaglandin. 
  Despite the fact that COX isoforms produce the same PGH2 precursor, 
COX-1 and COX-2 control very distinctive biological processes. COX-1 is a 
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regulator of homeostatic functions, it is expressed at low levels in various 
tissues and it provides maintenance of physiological functions such as 
platelet aggregation, renal water balance and gastric mucosa protection. On 
the other hand, COX-2 is not usually expressed and it appears in response 
to pathogens. Once its production is stimulated, its expression is high and it 
will cause the sudden production of PG (Cerella et al., 2010).  
  Inflammation is critically regulated by COX-2 and its derived products 
(PG) are important in the early stages of the inflammatory response and the 
end of it (Greene et al., 2011). The overproduction of PG has been mainly 
related to cancer, playing an essential role in oncogenesis and it is related to 
other diseases such as rheumatoid arthritis and diabetes (Cerella et al., 
2010; Schneider and Pozzi, 2011).  
1.3.3 Inhibition of COX-2 by polyphenols 
  Clinically, COX-2 is targeted by non-steroidal inflammatory drugs 
(NSAIDs) like aspirin, ibuprofen and naproxen and other selective inhibitors 
(e.g. celecoxib). Its long-term use has been banned due to its severe side 
effects such as damage to the gastric mucosa and relationship with the 
increase of cardiovascular diseases (Greene et al., 2011; Salvado et al., 
2012; Raman et al., 2008). As a result, the search for safer and more 
effective substitutes is still in progress.  
  Natural occurring compounds (e.g. flavonoids) and plant extracts 
represent a major source of bioactive compounds with potential anti-
inflammatory activity. For example, Cerella et al. (2010) have compiled 
information about the effects of curcumin, epigallocatechin gallate, 
resveratrol, apigenin, genistein, kaempferol, fisetin and chrysin on COX-2 
inhibition. In this case, they reported that curcumin supresses PG production 
and prevents COX-2 gene expression where the NF-κB pathway is strongly 
inhibited. Indeed, epigallocatechin gallate (EGCG), resveratrol, apigenin, 
genistein and kaempferol inhibit COX-2 expression (e.g. transcription) and 
EGCG has been linked to modify the activities of NF-κB and AP-1. Chrysin, 
a flavonoid from honey, inhibits expression of COX-2 at mRNA and protein 
levels. Investigation of plant extracts (e.g. green tea, German chamomile) 
has focused in the anti-inflammatory activity of specific compounds and it 
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has revealed effective inhibition of COX-2 expression and suppression of the 
NF-κB pathway (Peng et al., 2006; Srivastava et al., 2009).  
  Despite the suggested anti-inflammatory activity for various plant 
extracts and their major compounds, experimental information is still 
insufficient and the use of a broader range of techniques to support current 
results is needed. Animal models are commonly used to test plant extracts, 
but they do not produce enough information about the mechanism of action 
against inflammation (Webb, 2014). Indeed, cell culture studies explain 
specific pathways were flavonoids or plant extracts work against COX-2, but 
the differences in cell lines and the variation in inflammatory responses 
makes it more difficult to draw decisive conclusions (Lotito et al., 2011). 
 A different way to tackle this task is using analyses to determine COX 
inhibition at specific targets of the AA pathway. Some methods 
detect/measure reaction intermediates, meanwhile others detect final 
products (see Figure  1.6) (Petrovic and Murray, 2010). For example, 
O’Leary et al. (2004) used Caco-2 cells to measure the inhibition of COX-2 
by quercetin and its metabolites. As well, they performed an in vitro assay 
measuring the peroxidase activity of COX-2 (TMPD oxidation) testing 
quercetin, its metabolites, and DuP-697 which is a selective COX-2 and a 
feeble COX-1 inhibitor. The combined techniques gave more information 
and a better approach, but increased the cost and time of analysis. As a 
consequence, new techniques such as liquid chromatography and mass 
spectrometry have been more used by researchers.  
  Mass spectrometry has emerged as a powerful tool to detect specific 
analytes (e.g. PG) which can be identified in a single run after they have 
been isolated using liquid-liquid extraction. Cao et al. (2010); (2011), have 
reported a faster, more convenient and less expensive cell-free assay to 
determine the inhibition of COX-2 by bioactive compounds. The in vitro 
assay is carried out at small scale (Eppendorf tubes) using purified COX-2 
enzyme (human/ovine) and it includes a deuterium labelled standard 
(surrogate standard = d4-PGE2) to account for any losses during sample 
handling. Next, a liquid-liquid extraction is performed to obtain the PGE2 and 
surrogate, and the concentration obtained is measured using LC-MS2.  
- 15 - 
 
 
 
Figure ‎1.6 The AA pathway and the assays that can be used to 
measure activity/inhibition of COX-2. Modified from Petrovic and 
Murray (2010). TMPD = N,N,N',N'-tetramethyl-p-phenylenediamine. 
   The same proposal has been reported by Zhu et al. (2014) who 
compared the measurement of derivatized and underivatized PGE2. They 
used (carboxymethyl)trimethylammonium chloride hydrazide, also known as 
Girard’s reagent-T, to derivatize the PG. Derivatization is used to convert the 
carboxylic acid to a fixed-charge cationic derivative to improve detection 
sensitivity in LC-MS2 and it has been previously reported by Bollinger et al. 
(2010) who developed a new derivatization reagent, N-(4-
aminomethylphenyl)pyridinium (AMPP) for samples with limited amount of 
PGE2. As well, Deng et al. (2014) used the same in vitro assay, but included 
a magnetic ligand fishing to characterise green tea and measure COX-2 
inhibition at the same time. Both methodologies improve the measurement 
of COX-2 inhibition, but do not simplify the techniques already validated 
which it is the principal aim for the use of LC-MS. Indeed, measurements 
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using LC-ESI/MS are unusual, but they could provide an uncomplicated 
method to obtain equivalent results.   
 
1.4 Aim of this thesis and main objectives 
  This thesis aimed to investigate the effect of plant extracts and their 
major compounds on inflammation processes after they have been ingested. 
Our targets were the transformation of the plant extract and its major 
compounds by the first step of metabolism; the synthesis of phase II 
metabolites and their accurate measurement by LC-ESI/MS, and their 
inhibition of recombinant human COX-2.   
  These objectives were achieved by: 
1. Enzymatic hydrolysis of German chamomile and the identification of 
major compounds by LC-ESI/MS2 and LC-ESI/MS. German 
chamomile was used as a case plant extract. 
2. Biological synthesis of hesperetin sulfate using pig liver cytosol. The 
biological sulfation was accomplished by the synergic activity of 
PAPS and PNS. Indeed, biological samples (urine) were measured to 
compare the use of true standards and hydrolysis of metabolites in 
the quantification of these compounds. 
3. The major compounds of various plant extracts with potential anti-
inflammatory activity were used in an in vitro assay to screen their 
inhibitory activity against recombinant human COX-2. Next, selected 
compounds were used to perform a combined in vitro-LC-MS assay 
to determine their recombinant human COX-2 inhibition.  
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CHAPTER 2 Characterisation and enzymatic hydrolysis of 
German chamomile (Matricaria recutita) 
 
2.1 Abstract  
  German chamomile (GC) contains a high number of compounds that 
are scarcely reported in the literature. Improvements in identification 
techniques, such as liquid chromatography and mass spectrometry, have 
provided the means to detect a broader range of chemical structures. 
However, the lack of standard compounds makes it challenging to provide 
an accurate quantification. The work here presented aimed to identify the 
major compounds of GC by the combined methodology of LC-ESI/MS2 and 
LC-ESI/MS, and to mimic the transformation of these compounds after 
ingestion by using a multienzyme hydrolysis. Firstly, 25 compounds were 
identified and 8 compounds were accurately quantified in an aqueous extract 
of GC using true standards. Apigenin-7-O-glucoside was the most abundant 
flavonoid (5.7 g/100g dry weight) followed by luteolin-7-O-glucoside and 
apigenin (284 and 284 mg/100g dry weight respectively) which agreed with 
previous publications reporting that apigenin-7-O-glucoside and its derivative 
can be found in large quantities in GC. In addition, a two-enzyme hydrolysis 
procedure (hesperidinase and cellulase) was applied and samples before 
and after hydrolysis were analysed. A liquid-liquid extraction was performed 
after the hydrolysis was ended and it was found that acetonitrile was better 
remover than ethyl acetate. However, the concentration of aglycones 
(apigenin and luteolin) increased only up to 2.6% which might suggest that 
water-soluble compounds (glucosides) could have been lost during the 
extraction.     
 
2.2 Introduction 
German chamomile (GC), also known as Hungarian chamomile, 
mayweed, sweet false chamomile or wild chamomile, is cultivated in 
Germany, Hungary, Russia and other southern and eastern European 
countries. Traditionally, it has been used for minor infections in skin and 
mucosa. GC has been studied for its anti-inflammatory, analgesic and 
wound-healing properties, amongst other efficacies (Paulsen, 2002), and 
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has been listed by the European Food Safety Authority (EFSA) as a safe 
substance for human consumption (EFSA, 2012). Its use in the food and 
nutrition industry has increased during recent years and the awareness 
about its health benefits has drawn the attention of researchers. However, 
information about its specific activity and accurate composition is still scarce 
(Garcia-Alvarez et al., 2014).  
It has been reported that GC (flowers and plant) contains a vast 
number of components, including terpenoids, polyphenols (mainly flavonoids) 
and essential oils. Compounds such as monoterpenes, coumarins and 
flavonoids are considered to be bioactive ingredients (Srivastava et al., 
2010). For example, apigenin has been shown to decrease the release of 
inflammatory cytokines by inactivation of NF-κB and so defend against 
oxidative stress (Millington et al., 2014). Indeed, Kato et al. (2008) found that 
GC tea decreased blood glucose concentrations in fasted mice after their 
treatment with sucrose and inhibited ALR2 (aldose reductase) which 
transforms glucose into sorbitol and in diabetic conditions also produces 
fructose. 
Different techniques have been previously used to identify the 
composition of diverse plants and foodstuffs. For example, thin-layer 
chromatography, high performance liquid chromatography, supercritical fluid 
chromatography and others have been used to identify/quantify the 
polyphenol content of fruits and vegetables (Ignat et al., 2011) and these 
techniques have been transferred to plant extracts. Mass spectrometry 
techniques (MS2 and MS) have been previously used for the identification of 
the polyphenol content of GC and other plants (Raal et al., 2012; Lin and 
Harnly, 2012), but a whole profile of GC polyphenols is still a work in 
progress. Plants are an intricate blend of compounds which are not easy to 
identify and it is laborious to quantify them.  
Polyphenols in plants exist mainly as conjugates with one or two 
sugars attached (Bokkenheuser et al., 1987). These are mostly glucose or 
rhamnose, but can also be galactose, arabinose, xylose, glucuronic acid or 
other sugars. After the polyphenols have been ingested, the first step of their 
metabolism is the removal of the sugar by enzymes. The process can occur 
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in the food itself or in the gastrointestinal tract (Scalbert and Williamson, 
2000).  
 
Figure ‎2.1 Possible pathway of deglycosylation of polyphenols. 1. 
Hydrolysis by lactase phlorizin hydrolase; 2. Deglycosylation by β-
glucosidase and 3. Deglycosylation by gut microflora. Glc=glucose. 
Modified from Nielsen et al. (2006). 
    After a foodstuff or plant extract has been ingested, it is broken down 
and those compounds which survive the stomach acidity reach the small 
intestine and colon to be deglycosylated (see Figure 2.1) (Nielsen et al., 
2006). Specific enzymes (glycosidases and β-glucosidases) cut the sugars 
attached to liberate aglycones which will be further metabolised by other 
pathways. Hesperidinase is a mix of enzymes (glucosidases and 
rhamnosidases) which cuts rhamnose and glucose from the original 
compound (e.g. polyphenols) to liberate an aglycone (Wang et al., 2012b). 
Cellulase catalyses the hydrolysis of β-glucosides to remove glucose and 
yieds free polyphenols to its aglycone form (Yan and Wu, 2013). Both 
enzymes are produce by the fungi Aspergillus niger and have been 
separately used to chemically mimic human digestion.   
  In this study, two mass spectrometry techniques were performed (MS 
and MS2) to identify and quantify the major compounds of GC. The 
methodology was developed to be a straightforward approach to analyse 
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plant extracts and determine their polyphenol profile, both before and after 
hydrolysis.  
  
2.3 Materials 
German chamomile (Matricaria recutita), apigenin, luteolin, 
umbelliferone, apigenin-7-O-glucoside, luteolin-7-O-glucoside, 3,4-O-
dicaffeoylquinic acid, 3,5-O-dicaffeoylquinic acid and 4,5-O-dicaffeoylquinic 
acid were provided by PhytoLab (Vestenbergsgreuth, Germany) as part of 
the PlantLIBRA project. Ascorbic acid, sodium acetate, and hesperidinase 
and cellulase from Aspergillus niger were purchased from Sigma-Aldrich 
(Dorset, UK). Organic solvents were purchased from different suppliers: 
acetic acid and methanol from Sigma-Aldrich (Dorset, UK); ethyl acetate and 
formic acid from Fisher Scientific (Loughborough, UK); acetonitrile from 
VWR (Lutterworth, UK). All water refers to deionised Millipore water 
(Hertfordshire, UK) otherwise stated.  
 
2.4 Methods 
2.4.1 Screening of German chamomile by LC-ESI/MS2. 
 Matricaria recutita, also known as German chamomile was provided 
by Phytolab as dry extract previously extracted with 60% ethanol, dried and 
mixed with maltodextrin to increase its solubility (50:50, w/w). German 
chamomile (GC) was dissolved in water and prepared every time prior to 
analysis. In collaboration with our project, this analysis was performed by Dr. 
Asimina Kerimi using an Agilent 1200 HPLC coupled with a 6410 LCMS 
triple quadrupole fitted with an electrospray ionisation used in negative mode 
(Workingham, UK). An analytical column, Kinetex C18 (2.10x150 mm, 2.6 
µm) was used for the separation and was kept at 35°C. The injection volume 
was 5 µL at flow rate of 0.25 mL/min. Mobile phase A consisted of 95% 
water, 5% acetonitrile and 0.1% formic acid and mobile phase B consisted of 
95% acetonitrile, 5% water and 0.1% formic acid. Elution started at 0% 
solvent B, reached 10% after 5 min and increased up to 25% after 5 min 
more. At 20 min solvent B was 35% and rose up to 50% at 25 min. This 
gradient was kept until 30.5 min when it was increased to 100%. Then, it 
was maintained for 5 min more and at 36 min decreased to 0%. The column 
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was equilibrated until 41 min. Each compound was compared with 
references from the literature (see Table 2.2) and only eight were matched 
with their respectively true standard (see 2.4.3) kindly provided by PhytoLab.  
2.4.2 Enzymatic hydrolysis of German chamomile. 
German chamomile was hydrolysed using a modified method from 
Pimpão et al. (2013). Firstly, GC was prepared at 20 mg/mL (w/v) with 0.1 
mM ascorbic acid. However, due to its 50% maltodextrin content, the 
concentration was actually 10 mg extract/mL. The solution was adjusted to 
pH 3.8 with 0.2 M acetate buffer and 0.02 U/mL hesperidinase was added 
[1U=333 mg of protein and is defined as the amount required to liberate 1.0 
µmol of glucose from hesperidin per minute at pH 3.8 at 40°C]; so, it was 
incubated for 16 hr at 40ºC/70 rpm. Then, the pH was increased to 5 using 
0.2 M sodium acetate and incubated for 4 hr at 37ºC with 20 U/mL cellulase 
[1 U=0.885 mg of protein and is defined as the amount required to liberate 
1.0 µmol of glucose from cellulose in 1 hr at pH 5 at 37°C] and the mix was 
shaken at 70 rpm. The reaction was stopped using 1:2 pure organic solvent 
(ethyl acetate or acetonitrile) and centrifuged at 4ºC/3 000 g for 10 min. 
Supernatant was separated and this procedure was followed twice more. 
The three different fractions were mixed, aliquoted and evaporated under 
vacuum (Genevac, HPLC fraction, 30-35°C) to obtain tubes with theoretical 
1.11 mg/mL (w/w) concentrated sample. Then, samples were kept at -20ºC 
and reconstituted prior to LC-ESI/MS analysis with 30% methanol:water (v/v). 
 
2.4.3 Identification and quantification of eight compounds of GC dissolved in 
water and after enzymatic hydrolysis by LC-ESI/MS. 
2.4.3.1 Mass spectrometry 
  Samples of GC (with/without hydrolysis) were characterised using a 
Shimadzu LC-2010 HT coupled with a LCMS-2020 quadrupole mass 
spectrometer fitted with an electro spray ionisation source (Milton Keys, UK). 
A Kinetex C18 analytical column (2.10x150 mm, 2.6 µm) was used for the 
separation and was maintained at 35ºC. The injection volume was 10 µL at 
flow rate of 0.25 mL/min. The running programme from screening (see 2.4.1) 
was followed and the same solvents composition was employed. Each 
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compound was identified according to its mass-to-charge ratio in negative 
mode (m/z(-)) and compared to their respective true standard. Their general 
characteristics can be seen in Table 2.1.  
 
Table ‎2.1 Chosen compounds identified and further quantified in GC 
and two treated samples. Commercially-available standards were used 
to ensure their appearance.  
Compound 
Molecular 
weight 
(g/mol) 
RT 
(min) 
Structure 
Umbelliferone 162.15 11.7 
 
Apigenin 270.24 20.9 
 
Luteolin 286.24 18.1 
 
Apigenin-7-O-
glucoside 
432.38 15.1 
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Luteolin-7-O-
glucoside 
448.38 13.9 
 
3,4-
Dicaffeoylquinic 
acid 
516.46 14.3 
 
3,5-
Dicaffeoylquinic 
acid 
516.46 14.7 
 
4,5-
Dicaffeoylquinic 
acid 
516.46 15.3 
 
Glc=glucose 
2.4.3.2 Quantification using true standards 
  The concentration of eight compounds (see Table 2.3) in each 
sample was determined using external calibration. Stock solutions were 
prepared using 100% DMSO. Then, compounds were diluted in a mix 
methanol/water to reach < 1% DMSO. The curves were produced using a 
concentration range of 0.5 nM to 90 µM. Values from 5 to 30 µM were used 
to plot seven calibration curves and values from 5 to 70 µM were used for 
apigenin aglycone. The coefficient of determination was ≥ 0.97.  
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2.5 Results  
2.5.1 Profile of German chamomile by LC-ESI/MS2. 
  In collaboration with our project, Dr. Asimina Kerimi performed a 
screening of GC using a LC-ESI/MS2 which followed various polyphenols 
already reported in the literature (see Table 2.2). Polyphenols were identified 
using their specific transitions in negative mode and published reports 
notifying their appearance in GC. The specific characteristics used for this 
purpose can be seen in Table 2.2. This screening provided general 
information about the composition of GC and further analysis were based on 
these results.  
2.5.2 Identification of major compounds of German chamomile by LC-
ESI/MS. 
 After the screening by LC-ESI/MS2 was performed (see 2.5.1) GC 
was analysed by LC-ESI/MS and eight chosen polyphenols were identified 
(see Figure 2.2) in the sample dissolved in water (without hydrolysis).  
 
Figure ‎2.2 MS chromatography of GC dissolved in water (A: without 
hydrolysis). Total Ion Current (TIC) for GC and specific mass-to-charge 
ratio (m/z) in negative mode for identified polyphenols: umbelliferone 
(I) retention time (RT)= 11.7 min; apigenin (II) RT=20.9 min; luteolin (III) 
RT=18.1 min; apigenin-7-O-glucoside (IV) RT=15.1 min; luteolin-7-O-
glucoside (V) RT=13.9 min; 3,4-dicaffeoylquinic acid (VI) RT=14.3 min; 
3,5-dicaffeoylquinic acid (VII) RT=14.7 min and 4,5-dicaffeoylquinic acid 
(VIII) RT=15.3 min.    
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Table ‎2.2 Characteristics of compounds identified in German chamomile (GC) using LC-ESI/MS2 detection and reference in 
the literature.    
Compound name 
Precursor 
ion 
Product 
ion 
Fragmentor 
Collision 
energy 
RT RT RT RT Reference 
Protocatechuic acid aglycone 153 109 135 10 5.3    Guimaraes et al. (2013) 
Umbelliferone aglycone 161.1 133 135 20 7.9 9.2 12.3  Novakova et al. (2010) 
Ferulic acid (FA) aglycone 193 149 135 10 10.1 12.3   Guimaraes et al. (2013) 
Apigenin aglycone 269.2 151.2 135 20 20.6    
Novakova et al. (2010); Matic et al. (2013); Lin and 
Harnly (2012) 
Luteolin aglycone 285.2 133.1 135 25 17.8    Novakova et al. (2010); Lin and Harnly (2012) 
Kaempferol aglycone 285.2 151.1 135 20 17.7    Novakova et al. (2010) 
Quercetin aglycone 301.1 151.2 135 20 17.5    Kato et al. (2008) 
Isorhamnetin aglycone 315 300.3 135 20 21.5    Novakova et al. (2010) 
Coumaroylquinic acid aglycone 337 191 135 30 11.2    Guimaraes et al. (2013) 
4O- caffeolyquinic acid (CQA)  353 173 135 30 9.3    Guimaraes et al. (2013); Matic et al. (2013) 
3O-CQA 353 179 135 30 6.6    
Guimaraes et al. (2013); Matic et al. (2013); Lin and 
Harnly (2012) 
5O-CQA 353 191 135 30 9.5    Guimaraes et al. (2013); Matic et al. (2013) 
cis/trans FA hexoside 355 149 135 30 10.2    Guimaraes et al. (2013) 
cis/trans FA hexoside 355 193 135 30 10.2    Guimaraes et al. (2013) 
5O- feruloylquinic acid  367 194 135 30 11.8 13.7   
Guimaraes et al. (2013); Matic et al. (2013); Lin and 
Harnly (2012) 
Dimethoxy-cinnamic acid 
hexoside 
369 189 135 30 14.7 16.9 19.5  
Guimarães et al. (2013) 
Luteolin 7 O-glucoside 447 285 135 25 13.4 14.5   Guimaraes et al. (2013); Lin and Harnly (2012) 
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Quercetin 3 O-glucoside 463 301 135 25 12.5 13.1   
Novakova et al. (2010); Lin and Harnly (2012) 
Guimarães et al. (2013); Novakova et al. (2010); Lin 
and Harnly (2012) 
Quercetin 3 O-glucuronide 477 301 135 35 13.3 14.5   Lin and Harnly (2012) 
Myricetin O-hexoside 479 317 135 25 12.0    Guimaraes et al. (2013) 
Luteolin O-acylhexoside 489 285 135 30 14.6 15.9   Guimaraes et al. (2013) 
di-CQA 515 353 135 30 13.8 14.1 14.7  
Guimaraes et al. (2013); Matic et al. (2013); Lin and 
Harnly (2012) 
Kaempferol 3 O-rutinoside 593 285 135 30 13.1    Lin and Harnly (2012) 
Quercetin 3 O-rutinoside 609 301 135 35 12.4    Lin and Harnly (2012) 
FA hexoside dimer 711 193 135 35 10.2 12.3 12.9 13.9 Guimaraes et al. (2013) 
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   Then, commercially-available standards were used to verify the 
nature of the eight compounds identified. This procedure provided validation 
of the retention time here reported. A typical chromatogram is shown in 
Figure 2.3.  
 
Figure ‎2.3 Typical MS chromatogram for validation of occurrence of a 
selected compound (apigenin-7-O-glucoside). TIC of a commercially 
available apigenin-7-O-glucoside (A) RT= 15.1 min dissolved in 
ethanol:water (10:90, v/v) and GC dissolved in water (B).  
 
2.5.3 Effect of enzymatic hydrolysis on GC and identification of selected 
compounds.  
  German chamomile was enzymatically hydrolysed to determine the 
effect of gastrointestinal digestion, using hesperidinase and cellulase to 
mimic human digestion. Also, two different organic solvents (acetonitrile and 
ethyl acetate) were tested to choose the most efficient method for liquid-
liquid extraction. Then, identification by LC-ESI/MS was performed following 
the protocol reported in 2.4.2. The chosen eight compounds (see 2.5.2) were 
also followed and their appearance can be seen in Figure 2.4-2.5. Each 
figure shows a different treatment from liquid-liquid extraction.   
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Figure ‎2.4 MS chromatography of GC fraction hydrolysed and 
extracted with acetonitrile. Total Ion Current (TIC) for each sample and 
specific mass-to-charge-ratio (m/z) in negative mode for identified 
polyphenols: umbelliferone (I) retention time (RT)=11.7 min; apigenin 
(II) RT=20.9 min; luteolin (III) RT=18.1  min; apigenin-7-O-glucoside (IV) 
RT=15.1 min; luteolin-7-O-glucoside (V) RT=13.9 min; 3,5-
dicaffeoylquinic acid (VI) RT=14.7 min and 4,5-dicaffeoylquinic acid 
(VII) RT=15.3 min.  
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Figure ‎2.5 MS chromatography of GC fraction hydrolysed and 
extracted with ethyl acetate. Total Ion Current (TIC) for each sample 
and specific mass-to-charge-ratio (m/z) in negative mode for identified 
polyphenols. The compounds (I-VI) and retention time are stated in 
Figure 2.4.   
 
  It was found that seven of the eight compounds, identified in the 
sample dissolve in water, were still present after hydrolysis. Some (e.g. 
umbelliferone, apigenin) increased their MS signal after hydrolysis, 
suggesting the transformation from glucoside to aglycone. However, this 
phenomenon was not seen in the other compounds.  
  Next, calibration curves for the chosen polyphenols were produced 
and can be seen in Figures 2.6-2.9.  Due to the variability in equations, the 
limit of detection (LOD) and limit of quantification (LOQ) were practically 
determined at 500 nM and 5 µM respectively for all compounds. The 
abundance of each identified polyphenols in every sample is reported in 
Table  2.3. 
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Figure ‎2.6 Calibration curve for umbelliferone and 3,5-dicaffoylquinic 
acid using commercially available standards. N=3 biological replicates 
and 1 technical measurement.  
 
 
Figure ‎2.7 Calibration curve for apigenin and apigenin-7-O-glucoside 
using commercially available standards. N=3 biological replicates and 
1 technical measurement. 
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Figure ‎2.8 Calibration curve for 3,4 and 4,5-dicaffoylquinic acids using 
commercially available standards. N=3 biological replicates and 1 
technical measurement. 
 
 
Figure ‎2.9 Calibration curve for luteolin and luteolin-7-O-glucoside 
using commercially available standards. N=3 biological replicates and 
1 technical measurement. 
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Table ‎2.3 Concentration (mg/100g dw) of each selected polyphenol in 
samples dissolved in water and after hydrolysis and extraction by 
different organic solvents (acetonitrile/ethyl acetate). Data from 3 
biological samples, 1 technical measurement and ± SD.  
Compound m/z(-) RT 
(min) 
Dissolved in 
water 
Acetonitrile 
fraction 
Ethyl acetate 
fraction 
Umbelliferone 161 11.7 70.3 ± 1.1 154.9 ± 0.6 139.3 ± 0.9 
Apigenin 269 20.9 245.3 ± 6.4 376 ± 23 204.2 ± 3.9 
Luteolin 285 18.1 6.3 ± 0.3 18.1 ± 0.9 7.9 ± 0.1 
Apigenin-7-O-
glucoside 
431 15.1 5683.7 ± 159.7 575.1 ± 6.6 315.7 ± 3.2 
Luteolin-7-O-
glucoside 
447 13.9 284.1 ± 3.0 11.8 ± 0.1 5.2 ± 0.01 
3,4-
Dicaffeoylquinic 
acid 
515 14.3 116.4 ± 0.5 ND ND 
3,5-
Dicaffeoylquinic 
acid 
515 14.7 82.1 ± 1.3 10.4 ± 0.2 7.7 ± 0.4 
4,5-
Dicaffeoylquinic 
acid 
515 15.3 98.3 ± 1.2 10.7 ± 0.3 10.9 ± 3.2 
ND. Not detected, dw= dry weight, SD= standard deviation.  
  This characterisation provided sufficient information to perform further 
analysis and the purification of those GC polyphenols which are not 
commercially-available (e.g. ferulic acid hexoside).  
 
2.6 Discussion 
  Plant extracts and their polyphenol content have been a major 
research interest, as it has been suggested that they may provide health 
beneficial effects. For this reason, precise analytical techniques have been 
used to identify extract compositions and their application has been 
successful (Novakova et al., 2010; Guimaraes et al., 2013). In general, MS 
techniques are mainly used to identify and clarify chemical structures of 
specific compounds, such as polyphenols (Ignat et al., 2011). Liquid mass 
spectrometry, particularly ESI/MS, has been used to identify GC polyphenols 
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(Lin and Harnly, 2012). Although it is a powerful technique, it does not 
identify isomers, losing the ability to specify the site of substitution in the 
polyphenol structure. However, its simplicity in comparison with LC-ESI/MS2, 
GC-MS and NMR gives a substantial advantage over these other techniques. 
 Recently, GC polyphenols from dried chamomile flowers were 
identified by Lin and Harnly (2012)  using LC-PDA-ESI/MS, but no 
quantification was reported. Also, Matic et al. (2013) analysed GC tea 
(infusion and decoction) by LC-MSD-TOF-ESI/MS and only reported the 
total phenolic content using the Folin-Ciocalteu method. It is a common 
practice to determine the polyphenol concentration by the Folin-Ciocalteu 
method which provides imprecise data about the polyphenol content in a 
sample. In fact, it has been showed that different substances, as vitamin C 
and tannins, interfere with the assay (Georgé et al., 2005) and then could 
possibly lead to false results. Therefore, this technique must be used in 
combination with a more reliable methodology such as LC-MS.  
 Research has focused on identifying and quantifying apigenin-7-O-
glucoside and its derivatives (Švehlıḱová et al., 2004; Srivastava and Gupta, 
2009; Avula et al., 2013)  but less attention has been paid to other 
compounds. Our methodology identified many compounds previously 
reported in different GC extracts (see Table 2.2). Indeed, it was possible to 
positively quantify eight compounds (see Table 2.3). The limit of detection 
and quantification (LOD and LOQ) here reported are lower than those 
already reported by Boiteux et al. (2014) who detected apigenin at 107 µM 
and quantified it at 355 µM. Raal et al. (2012) provided  information about 
the polyphenol content of 13 commercial German-chamomile teas packaged 
in different countries and purchased in Estonia. These values can be seen in 
Table 2.4 in comparison with our sample dissolved in water (A). 
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Table ‎2.4 Content of major polyphenols (mg/100 g dw) in 13 
commercial samples and in our sample dissolved in water (A=without 
hydrolysis).  
 Samples 
Compound A 1 2 3 4 5 6 7 8 9 10 11 12 13 
Apigenin glu 5684 431 32 450 213 113 227 313 60 70 560 80 150 186 
Luteolin glu 284 254 80 260 113 87 133 87 90 40 260 18 77 78 
3,4-dcqa 116 354 32 260 93 207 193 153 150 110 250 58 147 68 
3,5-dcqa 82 523 80 570 173 300 360 320 190 230 500 170 607 198 
4,5-dcqa 98 392 24 350 93 153 227 187 110 80 300 102 260 78 
Glu=glucoside, dcqa=dicaffeoylquinic acid; dw= dry weight. 1- Belin, 2- Wilken Tee, 3-Eko 
Natura, 4- Švenčionių vaistažoles, 5-Teekanne, 6-Rimi order, 7-Tea Trader, 8-Laplanta, 9-
Bigelow, 10-Loodusravi, 11-Kubja Ürt, 12-Vadi Gild and 13-Elujõud.  
  They did not report their specific parameters of analysis (LOD and 
LOQ) for their quantification, but specified that each compound was 
identified comparing their fragmentation spectra (MS2) to commercial 
standards or reports in the literature. They used calibration curves of 
chlorogenic acid, luteolin aglycone and apigenin aglycone for the 
quantification of apigenin glucoside, luteolin glucoside and the three 
dicaffeoylquinic acids (3,4-, 3,5-, 4,5-), and the quantification was done using 
the ratio of molecular weights of the related standard compounds. The 
concentration of apigenin glucoside in their samples varied from 32 (Wilken 
Tee; Germany) to 560 mg/100g dw (Loodusravi; Estonia) which was lower 
than our sample dissolved in water (5683.7 mg/100g dw). In the case of 
luteolin glucoside, samples varied from 18 (Kubja Ürt; Estonia) to 260 
mg/100 g dw (Eko Natura- Poland; Loodusravi- Estonia). Our reported value 
for the sample dissolved in water (284.1 mg/100g dw) was higher than all 
the amounts reported. However, our comparison cannot be precise due to 
the lack of information about the specific glucoside measured by the 
publication. The concentration of 3,4-dicaffeoylquinic acid in our report 
(116.4 mg/100g dw) was similar to the concentration found in their sample 
Bigelow (USA) (110 mg/100 g dw). The sample Belin (Poland) showed the 
highest concentration (353.8 mg/100g dw) of 3,4-dicaffeoylquinic acid. Next, 
3,5-dicaffeoylquinic acid concentration in the 13 samples varied from 80 
(Wilken Tee) to 606.7 mg/100g dw (Vadi Gild). Only the lowest concentration 
matched our finding from the sample dissolved in water (82.1 mg/100g dw). 
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Finally, our measurement of 4,5-dicaffeoylquinic acid (98.3 mg/100g dw) 
was only comparable with the sample Švenčionių vaistažoles (Lithuania) 
(93.3 mg/100g dw). Discrepancy in our results could be attributed to our use 
of true standards instead of an indirect measurement for the quantification of 
each compound. The indirect measurement might have overestimated the 
concentration found in each sample, but other factors could have also 
influenced such as the preparation method, place of purchase and tea 
composition (tea leaves, flowers, etc).    
  Novakova et al. (2010) quantified methanolic extracts from loose tea 
and tea bags using a LC-ESI/MS2 method. Their LOQ (5 - 50 nM) was up to 
1000x lower than our method. This can be explained by the precision of the 
equipment used for their analysis. As it has been stated before, the inability 
of LC-ESI/MS to identify isomers will decrease the specificity of the 
identification which it might have a negative effect in the MS response, 
reducing the signal of each compound. They reported average values for 
apigenin-7-glucoside, apigenin, luteolin and umbelliferone in µmol/L (µM) in 
both types of samples (loose tea and tea bags). The comparison with our 
results cannot be 100% certain, since the change from µM to mg/100g dw 
was done using only the information provided in their article (see 2.3 in 
publication) and the results can be seen in the Table 2.5.  
Table ‎2.5 Average content of 4 polyphenols (mg/100g dw) in 16 
commercial samples from methanolic extracts of loose tea and tea 
bags, and content in our two liquid-liquid extractions. 
 mg/100 g dw 
Compound Loose tea Tea bags 
Fraction 
Acetonitrile 
Fraction 
Ethyl acetate 
Apigenin-7-
glucoside 
138 65 575 316 
Apigenin 21 9 376 204 
Luteolin 3 < 3 18 8 
Umbelliferone 8 < 8 155 139 
dw=dry weight  
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   It was found that our two samples extracted with acetonitrile and ethyl 
acetate had higher concentrations of these 4 compounds in comparison with 
their methanolic fractions, where apigenin in tea bags presented the highest 
difference (up to 42x less than fraction acetonitrile). They reported that loose 
tea contained up to ½ higher concentration of apigenin and apigenin-7-O-
glucoside than tea bags, suggesting that the manufacturing process has a 
negative effect on the content of major polyphenols.  
  Finally, one of the most recent reports on GC (Guimaraes et al., 2013) 
presented a wider list of compounds using two different methods of sample 
preparation (infusion and decoction). According to their report, the major 
compound found in GC was luteolin-O-acylhexoside which we identified, but 
not quantified. The concentration of luteolin-7-O-glucoside in their sample 
extracted with methanol (60 mg/100g dw) was higher from our samples 
extracted with acetonitrile and ethyl acetate. However, our sample dissolved 
in water (284 mg/100g dw) was higher than their two methods of preparation 
(170 and 90 mg/100g dw from infusion and decoction respectively). We did 
not detect 3,4-dicaffeoylquinic acid in treated samples (liquid-liquid 
extraction), but we measured 116 mg/100 g dw in the sample dissolved in 
water. They quantified it in their three samples and at higher concentration 
(330-730 mg/100g dw) than our reported value. Low concentration (10-8 
mg/100g dw) of 3,5-dicaffeoylquinic acid was found in our both treated 
samples in comparison with their value reported for their sample extracted 
with methanol (100 mg/100g dw). Their samples from infusion and decoction 
varied from 260 to 160 mg/100 g dw respectively. These values were higher 
than our sample dissolved in water (82 mg/100g dw). The compounds 3,4- 
and 3,5-dicaffeoylquinic acid were identified according to their fragmentation 
patterns and previous reports of their appearance, but it is not determine if a 
calibration curve was used to perform their quantification.  
 Overall, plant extracts are not only affected by external factors such 
as harvesting, growing season, processing, etc.; others might also influence 
the polyphenol content in the plant (Alfaro et al., 2013). Polyphenols are 
transformed inside of the human body by the gastrointestinal tract and this 
phenomenon was mimicked by enzymatic hydrolysis. Two groups of 
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enzymes: hesperidinase and cellulase were used to mimic those enzymes 
found in the gut microflora (β-glycosidases and α-L-rhamnosidase) and 
intestinal cells (β-D-glucosidases) (Scalbert and Williamson, 2000). This 
approach has been reported since the late 1980’s by Bokkenheuser et al. 
(1987) using intestinal bacteria from humans to hydrolyse quercetrin and 
robinin and obtain their aglycones, quercetin and kaempferol respectively. 
They also suggested that other intestinal species may perform the same 
hydrolysis. Then, the methodology followed in our experiments was 
previously tested in a complex mix of polyphenols in berries (Pimpão et al., 
2013) which showed that a combination of enzymes was more efficient to 
yield a higher concentration of aglycones than individual enzymes. Further, 
this method was tested in five different fruit matrices which revealed its 
versatility and potential use in other plant-based materials. We performed 
this method using the same combination of enzymes. In addition, GC 
polyphenols were extracted using two different organic solvents: acetonitrile 
and ethyl acetate.  
  Firstly, as it was expected, the concentration of the aglycone forms 
after hydrolysis and liquid-liquid extraction (umbelliferone, luteolin and 
apigenin) increased by up to 2.3x. Indeed, the concentration of conjugates 
(e.g. apigenin-7-O-glucoside) decreased more than 90% and some could not 
be detected (3,4-dicaffeoylquinic acid). It was assumed that once conjugates 
were hydrolysed, the concentration of its aglycones after extraction (apigenin 
and luteolin) would increase in a similar ratio. However, this did not happen 
as expected. For instance, luteolin-7-O-glucoside decreased more than 95%, 
but luteolin only increased up to 2.6%. The most drastic loss was seen in the 
concentration of apigenin-7-O-glucoside and its aglycone (apigenin) which 
did not increase more than 2%. One of the possible reasons for this 
phenomenon is due to solubility of the compounds which suggested that no 
hydrolysed glucosides were lost during the liquid-liquid extraction. 
Glucosides are more water-soluble than their aglycones and this might have 
affected their quantification. It is recommend that after enzymatic hydrolysis 
a liquid-liquid extraction should be carried out with other organic solvents 
miscible in water such as 2-propanol or ethanol. Methanol has been 
previously used by Guimaraes et al. (2013), but did not show effective 
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extraction of the most abundant compounds in GC, apigenin and its 
derivatives. Also, Ignat et al. (2011) reported that methanol in different 
aqueous mixes has been generally used for the extraction of these 
polyphenols, but it can promote spontaneous methylation and then deliver 
incorrect results (Xie et al., 1993). Despite seeing a better extraction using 
acetonitrile, the concentration of each compound might have been 
underestimated.  
 In summary, the characterisation of a plant extract is an essential step 
towards a better understanding of the potential effects on human health. A 
methodology using LC-ESI/MS will provide the necessary information to 
select those compounds with more scientific interest, but it is important to 
take into account its limitations. Also, if two methodologies are combined 
(MS2 and MS) the time of analysis will decrease and its accuracy will 
improve. Additionally, enzymatic hydrolysis will help to identify and quantify 
the polyphenol content of plant samples which by nature is a complex 
mixture. This approach can provide a complete profile of the plant which will 
improve the knowledge collected so far. 
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CHAPTER 3 Polyphenol phase II conjugation: sulfation of 
hesperetin using pig liver cytosol and identification by LC-
ESI/MS 
 
3.1 Abstract 
   Identification and quantification of polyphenol phase II metabolites 
has been an ongoing challenge for research, and is required to understand 
and determine the potential health benefit of polyphenols. The main 
methodology to avoid this challenge has been through enzymatic hydrolysis. 
However, due to the technique’s limitations, it provides only general 
information of the phase II metabolites, but cannot report accurate 
quantification data. The objectives of this investigation were to develop a 
reproducible high-yielding method to sulfate polyphenols, to identify the main 
form biologically synthesised in humans and to analyse urinary samples to 
confirm their presence in biological fluids. The sulfation was achieved using 
pig liver cytosol and p-nitrophenyl sulfate (PNS) as co-cofactor, which 
produced up to 90% transformation. Hesperetin was used as the 
experimental polyphenol and the sulfated form was identified as hesperetin-
3'-O-sulfate. Urine samples from a crossover human study were collected 
and analysed by Dr. Tristan P. Dew and Miss Isabella Procopiou using true 
standards for identification and quantification of hesperetin metabolites. The 
data was assessed, statistically analysed and interpreted by this researcher. 
Quantification by LC-ESI/MS showed an enhanced response of the sulfated 
form in comparison of its aglycone, which modified its concentration 
calculated in urine samples. This allowed the hesperetin excretion to be 
accurately quantified. The excretion data showed statistical difference 
between value brand and freshly squeezed orange juice (p=0.011). The 
individual excretion for each metabolite (hesperetin-7-O-glucuronide, 
hesperetin-3'-O-glucuronide and hesperetin-3'-O-sulfate) was also 
statistically different between value brand and freshly squeezed orange juice. 
The concentration of hesperidin ingested was significantly different in the 
three orange juices (p<0.001). The metabolite excretion was higher in freshly 
squeezed orange juice, even though the concentration of hesperidin 
ingested was the lowest.   
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3.2 Introduction 
  Polyphenols occurring naturally in plants can be classified into two 
groups, the flavonoids and the non-flavonoids (Crozier et al., 2009). In the 
group of flavonoids, flavanones are present almost exclusively in citrus 
fruits. Hesperetin-7-O-rutinoside (hesperidin) is one of the most common in 
oranges and mandarin (see Figure 3.1). Its aglycone form, without sugar 
moiety, hesperetin is present in only very small quantities in the plant, and 
mostly appears after the first step of metabolism.  
 
Figure ‎3.1 Hesperetin-7-O-rutinoside (hesperidin) structure. 
  Orange juice is one of the most widely consumed fruit juices in the UK, 
covering 54% of the fruit juices market (BSDA, 2014). Although its 
consumption has dropped during recent years, orange juice ingestion is still 
related to health benefits such as protection against oxidative-stress related 
to inflammation (Nakajima et al., 2014) and improvement in cognitive 
function in healthy older adults (Kean et al., 2015). After orange juice has 
been consumed, hesperidin undergoes cleavage and hesperetin is relased. 
Then, phase II reactions (sulfation, glucuronidation and methylation) occur 
as part of its absorption process (Nielsen et al., 2006). Ultimately, these 
metabolites circulate through the bloodstream and significant quantities are 
excreted in the urine. Hesperetin and its metabolites have been recently 
quantified in urine samples using authentic standards commercially available 
(Bredsdorff et al., 2010; Pereira-Caro et al., 2014). However, most of the 
publications have used enzymatic hydrolysis to split glucuronide and sulfate 
group(s) and release its aglycone. Even though this method is widely used, 
some flavonoids have been shown to be poor substrates for commercial 
enzymes (Vallejo et al., 2010; Farrell et al., 2011; Saha et al., 2012) which 
suggests an underestimation of their concentration. A series of 
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methodologies to chemically synthesise glucuronidated compounds have 
been reported (Khan et al., 2014) and only a few research papers have 
performed analysis and biological synthesis of sulfated forms (Takumi et al., 
2012; Bredsdorff et al., 2010; Brand et al., 2010; Mullen et al., 2010). 
Although these publications have positively identified hesperetin-3'-O-sulfate 
as the common monosulfate metabolite in urine after phase II metabolism, 
their methodology relies on differences in ion fragmentation in LC-MS2 or 
specific resonance frequency in NMR which increases cost, time of analysis 
and could potentially report misleading information. Therefore, knowing 
these limitations and the need for authentic standards, we have developed 
an accessible method to biologically sulfate flavanones and we compared it 
with a chemically synthesised standard. We introduced a regenerator of 
adenoside 3'-phosphate 5'-phosphosulfate (PAPS) called p-nitrophenyl 
sulfate (PNS) which has been previously reported as a sulfate donor 
(Koizumi et al. 1990;1991), but in the presence of adenosine 3',5'-
diphosphate (PAP) it donates its sulfate group and restores PAPS, thereby 
increasing the % transformed. The compound biologically synthesised was 
identified as hesperetin-3'-O-sulfate and it was used to quantify phase II 
metabolites in urine samples following orange juice consumption. To our 
knowledge, there is no reported methodology using our approach and it is 
the first data using an authentic standard to quantify hesperetin-3'-O-sulfate 
in urine samples. 
3.3 Materials 
Rutin, taxifolin and hesperetin were purchased from Extrasynthese 
(Genay Cedex, France). Potassium hydrogen phosphate and potassium 
dihydrogen phosphate were purchased from Alfa Aesar (Ward Hill, USA). L-
Ascorbic acid, adenosine 3'-phosphate-5'-phosphosulfate lithium (PAPS), 
DL-dithiothreitol (DTT), sodium sulphite, potassium 4-nitrophenyl sulfate 
(PNS) and formic acid were purchased from Sigma-Aldrich (Dorset, UK). 
Hesperetin-3'-O-sulfate (Hp3'SO4) was kindly provided by Dr. C. Morand 
(INRA, France). Hesperetin-3'-O-glucuronide (Hp3'Glu) and hesperetin-7-O-
glucuronide (Hp7Glu) were kindly donated by Professor Denis Barron 
(Nestle, Switzerland). Supermarket own-brand value range orange juice 
manufactured from concentrate, luxury range freshly squeezed orange juice 
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(Morrisons; Bradford, UK) and premium-brand (Tropicana; Boxford, UK) 
were purchased at a local supermarket (Morrisons; Leeds, UK). Pig liver 
cytosol suspension was prepared as described in 3.4.1. Ethyl acetate and 
acetonitrile were LCMS grade and purchased from VWR (Lutterworth, UK). 
Methanol HPLC grade was purchased from Fisher Scientific (Loughborough, 
UK) and ethanol absolute for HPLC use was purchased from Sigma-Aldrich 
(Dorset, UK). All water refers to deionised Milipore water (Hertfordshire, UK) 
unless otherwise stated.     
 
3.4 Methods 
3.4.1 Preparation of pig liver cytosol suspension 
Preparation of liver cytosolic suspension was performed using a 
modified version of a method by Campbell et al. (1987). Fresh pig liver 
purchased locally was submerged in an ice-cold 250 mM sucrose solution to 
remove excess of blood. The liver was blotted dry and a sample (13 g) was 
finely chopped with scissors then homogenised with 50 mL of ice-cold Tris-
HCl buffer (50 mM, pH 7.5) using a hand blender. The homogenate was 
separated in a refrigerated centrifuge (Beckman JA25.50; High Wycombe, 
UK) at 17,800 g for 10 min at 4°C. The resulting supernatant was decanted 
and further centrifuged for 90 min at 34,900 g at 4°C. The final supernatant 
was recovered, aliquoted and stored at -80°C for further use.    
3.4.2 Synthesis of polyphenol sulfate 
Biological sulfation was performed using a modified version of a 
method by Menozzi-Smarrito et al. (2011). The reaction was performed in 
potassium phosphate buffer solution (74 mM containing 100 µM ascorbic 
acid, pH 7.4) including adenosine 3'-phosphate 5'-phosphosulfate lithium 
(100 µM), DL-dithiothreitol (1mM) and sodium sulphite (10 mM) with or 
without potassium 4-nitrophenyl sulphate (various concentrations). The 
mixture was pre-warmed for 5 min at 37°C and a solution of hesperetin in 
ethanol (80 µM) was added. The reaction was initiated by the addition of the 
pig liver cytosol suspension and was incubated for 4 hrs at 37°C. The 
reaction was stopped by adding organic solvent (2:1, v/v) and vortexing for 
60 sec. Two organic solvents, acetonitrile (method 1) and ethyl acetate 
(method 2), were used to remove unreacted compounds and other impurities. 
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After the incubation time was over, ice-cold acetonitrile (method 1) was 
added to the mixture (2:1, v/v), vortexed for 60 sec and centrifuged at 17,000 
g for 15 min. The supernatant was collected and centrifuged again at 17,000 
g for 15 min. The last supernatant was collected and was analysed by LC-
ESI/MS.  
In a similar way, after the incubation time had finished, ice-cold ethyl 
acetate (method 2) was added to the mixture, vortexed for 60 sec and the 
supernatant was discarded. This process was repeated 2x. Then, the 
remaining pellet was treated as described in method 1. Samples that were 
not analysed were stored at -80°C.  
3.4.3 Semi-preparative chromatography and identification by LC-ESI/MS 
  Hesperetin sulfate was further purified via semi-preparative HPLC 
using a Shimadzu Prominence system (Milton Keys, UK) comprising a LC-
20AD XR with parallel double micro plunger, a temperature-control 
autosampler and a SPD-M20A diode array detector. The HPLC system was 
coupled to a FRC-10A fraction collector. A 20 µL sample was injected and 
analytes were separated using an eclipse XDB-C18 analytical column 
(4.6x50 mm, 1.8 µM; Agilent, Cheadle, UK) maintained at 30°C. Mobile 
phase A consisted of 0.5% formic acid in water and mobile phase B 
consisted of 0.5% formic acid in acetonitrile. Elution started at 5% solvent B 
at a flow rate of 1 mL/min. Solvent B was increased to 10% after 5 min, then 
rose up to 40% until 20 min and after 25 min reached 90%; this percentage 
was held until 29 min. The gradient returned to 5% solvent B over 1 min, and 
the column re-equilibrated until 33 min. Hesperetin sulfate was collected 
between 7 and 8.5 min and was identified using a similar chromatographic 
separation with a flow rate of 0.5 mL/min, injecting a 10 µL sample using a 
Shimadzu LC-2010 HT HPLC coupled with a LCMS-2020 quadrupole mass 
spectrometer fitted with an electro-spray ionisation source used in negative 
mode, detector -1.80 kV, DL temperature 250°C, nebulizing gas flow and 
drying gas flow 1.50 and 15 L/min respectively. The retention time and 
sensitivity of the method for hesperetin-3'-O-sulfate (Hp3'SO4) was 
evaluated using a chemically synthesised standard generously provided by 
Dr. C. Morand (INRA, France).  
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3.4.4 Human study to identify hesperetin metabolites from orange juice 
consumption 
  This crossover human study was carried out by Dr. Tristan P. Dew 
and Miss Isabella Procopiou in collaboration with our research project.  
3.4.4.1 Subjects 
  Fifteen healthy subjects (eleven females and four males) were 
recruited and all completed this study. Inclusion criteria included: age 22-27 
years, body mass index (BMI) 16.9-32.9 kg/m2. Exclusion criteria included: 
regular medication, gastrointestinal surgery and intestinal or metabolic 
disease. The study was approved by the Faculty research ethics committee 
MEEC (Maths, Engineering and Physical Sciences) 09-019 which followed 
institutional guidelines. 
3.4.4.2 Study design 
  The study was a 3-visit treatment with a randomised crossover design, 
including a wash out of 2 days prior to test day. Participants were provided 
with a food restriction list to avoid during the wash out and 24 hrs after 
orange juice consumption, including citrus and citrus derived food. 
Restricted foods included all types of juices, smoothies, jams, jellies, etc. 
After overnight fasting, baseline urine was collected prior to orange juice 
consumption. Doses of orange juice were administered on the basis of body 
weight (BW) (at the rate of 5 mL/kg BW). Next, a polyphenol-free breakfast 
and lunch were provided, and participants were asked to collect urine for 24 
hrs recording the collection time and any irregularities.  
3.4.4.3 Urine collection and processing  
  Urine was collected in sterilised and dried 3 L unisex collection 
vessels, each containing 3 g of ascorbic acid. The total volume of baseline 
and 24-hrs urine was recorded using the scale on the vessel and 10 mL 
aliquots were placed into 15 mL falcon tubes. To each 10 mL portion of urine, 
0.1 mL of 10% sodium azide was added and sample was vortexed for 10 
sec. If 24-hr urine was collected in two or more containers, all urine was 
mixed thoroughly before aliquots were taken. Samples were centrifuged at 
2,000 g for 10 min at 4°C (Centrifuge 5810 R Eppendorf, UK) and 
supernatants were removed and stored at -20°C until analysis.  
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3.4.4.4 Extraction of hesperetin conjugates from urine 
  Baseline and post-supplementation urine samples were extracted in 
duplicate from all participants. For each replicate, 200 μL of urine was mixed 
with 100 μL of rutin internal standard (2.5 μg/mL), 100 μL of HPLC grade 
ethanol and 800 μL of HPLC grade methanol. This solution was then placed 
in a shaking water bath (GLS Aqua 12 Plus, Grant Instruments Ltd, UK) at 
50˚C and 110 rpm for 10 min to solubilise the compounds. The mixtures 
were placed in a micro-centrifuge for 10 min at 17,000 g (IEC-MicroCL17, 
Thermo, Germany). The supernatant was removed as the first extract. The 
pellet was resuspended in 200 μL water, 100 µL of HPLC grade ethanol and 
800 µL of HPLC methanol and the extraction process was repeated. The 
primary and secondary supernatants were stored in a freezer at -20°C. After 
all samples were processed, the primary and secondary supernatants were 
dried using a centrifugal evaporator (Genevac EZ2plus Evaporation System, 
USA), initially using the HPLC program with the lamp off to achieve the 
evaporation of methanol and ethanol layer, followed by the aqueous 
program at 65˚C to evaporate the remaining urine-water layer. Completely 
dried samples were placed back into the freezer at -20°C until their 
reconstitution.  
3.4.4.5 Reconstitution of the dried samples 
  The dried samples were brought to room temperature and were 
reconstituted within 24 hrs of analysis. A 70 μL aliquot of HPLC grade 
methanol was added to secondary supernatant (see 3.4.4.4). This solution 
was vortexed, sonicated and placed in a shaking water bath for 10 min; then 
a 50 μL aliquot was combined with the corresponding primary extract. This 
mixture was vortexed, sonicated and placed in a shaking water bath. 
Subsequently, a 50 μL aliquot of 0.2% ascorbic acid (w/v) with 5 µg/mL 
taxifolin internal standard were added to the mix and vortexed until the 
samples were completely dissolved into the solution. This mixture was 
further centrifuged for 10 min at 17,000 g and the supernatant was 
transferred into amber HPLC vials. The determination of recovery was 
performed using blank urine spiked with hesperetin, hesperetin-7-O-
glucuronide (Hp7Glu) and hesperetin-3'-O-glucuronide (Hp3'Glu) at 
concentrations of 41.6, 4.16 and 0.42 µM in triplicate.  
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3.4.4.6 Orange juice composition 
  Each orange juice (freshly squeezed, value-brand and premium-
brand) was treated with aqueous methanol (80%, v/v). A 500 µL aliquot of 
orange juice was mixed with 10 µL of apigenin as internal standard (1 
mg/mL) and 490 µL of aqueous methanol. The sample was centrifuged at 
3,000 g for 5 min and the supernatant was collected. The pellet was washed 
three times using 500 µL of methanol each time and collecting all 
supernatants. Finally, a 0.2 µm PTFE filter was used to filter supernatants 
into HPLC vials. These were used in LC-ESI/MS quantification.  
3.4.4.7 Analysis of urinary hesperetin-metabolites by LC-ESI/MS 
  Orange juice and urine samples were analysed using a Shimadzu LC-
2010 HT HPLC coupled with a LCMS-2020 quadrupole mass spectrometer 
fitted with an electro spray ionisation source operated in negative mode, with 
a detector voltage of -1.80 kV, DL temperature 250°C, nebulizing gas flow 
and drying gas flow were set to 1.50 and 15 L/min respectively. The mass 
spectrometer was set to single ion monitoring (SIM) mode in negative mode, 
capturing data at mass-to-charge ratios (m/z) of 301, 303, 381, 477 and 609 
corresponding to hesperetin, taxifolin, Hp3'SO4, Hp3'Glu, Hp7Glu and rutin 
respectively. A 5 µL aliquot was injected and analytes were separated using 
a Kinetic C18 analytical column (2.1x150 mm, 2.6 µm; Phenomenex, 
Cheshire, UK) maintained at 35˚C. Mobile phase A consisted of 0.2% formic 
acid in a mix of water: acetonitrile (95:5, v/v) and mobile phase B consisted 
of 0.2% formic acid in a mix of acetonitrile:water (95:5, v/v). The flow rate 
was set at 0.26 mL/min. Elution started at 15% solvent B and remained until 
13.6 min. From 16.4 to 22 min solvent B was increased up to 35% and at 
23.4 min was increased to 90% and then held up to 27.2 min. At 30 min 
solvent B was decreased to 15% and the column was re-equilibrated until 37 
min.  
3.4.4.8 Statistical analysis of urine samples after orange juice consumption 
  IBM SPSS statistics 22 was used for all the statistical analysis 
(Portsmouth, UK) and orange juices were coded as 1, 2 and 3 
corresponding to freshly squeezed, premium brand and value brand to 
facilitate the evaluation. Data was assessed by Shapiro-Wilk’s test to 
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determine normality. The non-parametric analysis, Friedman test, was used 
for data not normally distributed to determine any significant difference 
among the variables. A one-way repeated measurement ANOVA was 
conducted for data normally distributed. Significance level was determined 
as p<0.05.  
    
3.5 Results 
3.5.1 Optimisation of hesperetin sulfate biosynthesis 
Biological synthesis of hesperetin sulfate was based on a modified 
method published by Menozzi-Smarrito et al. (2011). Even though previous 
work on hydroxycinnamic acids (Dr C.C. Wong, published) showed that 
human liver (diluted) sulfated these compounds, our early development work 
indicated that human pooled liver diluted was a poor driver of quercetin 
sulfation (< 1% transformation). Indeed, diluted cytosol from pig liver did not 
sulfate epicatechin. Then, cytosol from pig liver without dilution was used in 
further experiments for the transformation of hesperetin to hesperetin sulfate.  
The biosynthesis of sulfate compounds is a reaction where PAPS is 
the universal donor of the sulfate group and it is transformed to PAP 
(adenosine 3',5'-diphosphate) after the reaction has occurred. It has been 
reported by Tyapochkin et al. (2009) that PAPS can be regenerated  after 
being used in the reaction by PNS. Thus, the influence of PNS (20 mM) as 
co-cofactor of the reaction was investigated.    
Firstly, to establish an optimum incubation time, the reaction was 
followed from 1 to 4 hrs in presence of a sulfatase inhibitor (sodium sulphite). 
Samples for each hr (PAPS and PAPS+PNS) were prepared following the 
methodology above described (see 3.4.2). Every hr, samples were taken out 
from the water bath and the reaction was stopped. Next, samples were 
assessed to determine their content of hesperetin sulfate. After 1 hr, 
samples with PAPS reached 32%, increasing to just 38% after 4 hrs 
incubation. On the other hand, samples with PAPS+PNS reached up to 90% 
transformation after the first hr and they did not present major changes after 
four hours (80% transformation). There was no significantly difference for the 
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time (hours), but there was a significant difference between treatments 
(p<0.001).  
 
Figure ‎3.2 Hesperetin sulfate biosynthesis. Comparison between 
reaction with co-factor PAPS and reaction with mixture PAPS+PNS. 
N=3 biological replicates and 1 technical measurement, +SD.  
 The percentage of transformation was based on the appearance of 
sulfate versus loss of substrate after biosynthesis (see Figure 3.2). Further 
experiments were performed at 4 hrs and showed up to 90% transformation 
(see Figure 3.4). 
3.5.2 Purification of hesperetin sulfate and its identification using a 
chemically synthesised standard and LC-ESI/MS 
3.5.2.1 Method selectivity 
  All chromatograms were recorded following the mass-to-charge ratio 
of hesperetin aglycone (m/z 301) and its mono- and di-sulfates (m/z 381, 
461) in negative mode. Hesperetin aglycone was identified in all samples 
and its mono-sulfate (m/z 381) was only detected following biosynthesis.  
  Additionally, it was found that the use of 0.5% (v/v) formic acid in LC-
ESI/MS mobile phase increased the signal of sulfate metabolites in 
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comparison with 0.1% (v/v) formic acid, providing better separation and 
more stable signal (data not shown).  
3.5.2.2 Hesperetin sulfate pre-treatment 
  A liquid-liquid extraction using ethyl acetate and acetonitrile was used 
as pre-treatment before purification. The methodology followed can be seen 
in 3.4.2. No major changes were observed after using two organic solvents 
(ethyl acetate and acetonitrile) instead of one (acetonitrile) to extract 
hesperetin sulfate, as both delivered more than 90% transformation (data 
not shown).   
3.5.2.3 Identification of hesperetin sulfate 
  Hesperetin sulfate was collected following the methodology explained 
in 3.4.3. After several collections took place, the fraction was re-analysed in 
LC-ESI/MS and a chemically synthesised hesperetin sulfate was used to 
identify the monosulfate as hesperetin-3'-O-sulfate (Hp3'SO4) (see Figure 
3.3).  
 
Figure ‎3.3 TIC chromatograms of hesperetin sulfate and its standard. 
A) Chemically synthesised hesperetin-3'-O-sulfate; B) Hp3'SO4 using 
1.5 mM PNS and C) Hp3'SO4 using 20 mM PNS.  Retention time (RT) = 
16.7 min. 
 It was observed that after the sulfate sample was pre-treated (see 
3.5.2.2), an amount of PNS still remained in the mix. For this reason, 
different concentrations of PNS (1 to 20 mM) were tested to estimate the 
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minimum amount to perform the reaction which will not remain in high 
quantities in the supernatant. The molar ratio between hesperetin and PAPS 
was kept at 1:1.25 and only the concentration of PNS was modified (see 
Figure 3.4).  
 
Figure ‎3.4 Percentage of conversion of hesperetin to its sulfate 
conjugate after 4 hrs using different concentrations of PNS. N=3 
biological replicates and 1 technical measurement, ± SD.  
  From the lower concentrations, 1.5 and 3 mM yielded 94 and 95% 
transformation. The other concentrations yielded 90% or more, except for 15 
mM (86%). Further experiments were performed using 10x less PNS from 
initial experimentation (20 mM). The chromatography was improved and the 
transformation was not compromised after the modification (see Figure 3.3).  
3.5.2.4 Sensitivity of method for analysis of biosynthesis samples  
  The sensitivity of the analytical method was evaluated by determining 
the limit of detection (LOD) and limit of quantification (LOQ) of the sulfate by 
LC-ESI/MS. Hesperetin aglycone, Hp3'SO4 and a mix of both were analysed 
from 1 nM to 100 µM following the mass-to-charge ratio for each analyte 
(m/z 301 and 381) in negative mode. Compounds were dissolved in DMSO 
and diluted with ethanol/water at different ratios to provide a fully dissolved 
mix. The limits for hesperetin agycone were: LOD=1.1 µM and LOQ=3.7 µM. 
The limits for Hp3'SO4 were LOD=2.9 µM and LOQ=9.7 µM. These values 
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were calculated using the equation LOD=(SD/slope)*3 and 
LOQ=(SD/slope)*10. Visually, hesperetin aglycone and hesperetin sulfate 
were detected at 0.1 µM and they could be confidently quantified at 0.5 µM. 
The calibration curves can be seen in Figure  3.5. 
 
Figure ‎3.5 Calibration curves for hesperetin and Hp3'SO4 using single 
compounds and a mix of both. A) Hesperetin aglycone and B) Hp3'SO4. 
  It was observed that the MS signal for Hp3'SO4 in the mix was in 
average 2.3x more than hesperetin aglycone. Similarly, the MS signal of 
Hp3'SO4 measured as single compound was 1.4x more than hesperetin 
aglycone. As a result, a 2.3 correction factor was used in further 
quantification of Hp3'SO4, as hesperetin aglycone and Hp3'SO4 would be 
measured mixed together.  
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3.5.3 Analysis of different orange juices and how their consumption impacts 
hesperidin urinary phase II metabolites on humans 
3.5.3.1 Quantification of major polyphenols in orange juice 
  The concentration of hesperidin (which is the precursor of hesperetin 
and its metabolites) was assessed in each of the 3 orange juices used in the 
intervention study. Value brand orange juice contained the highest amount 
of hesperedin (276 mg/L) followed by the premium brand and freshly 
squeezed juice (189 and 177 mg/L respectively) (see Figure 3.6). Only 
traces of hesperetin and hesperetin-7-O-glucoside (< 0.01 mg/L) were 
detected.   
 
Figure ‎3.6 Hesperidin content of different orange juice samples. A) 
Value brand (276 ± 21.6 mg/L), B) freshly squeezed (177 ± 18.3 mg/L) 
and C) premium brand (189 ± 7.8 mg/L). N= 3 biological replicates and 1 
technical measurement, ± SD.  
3.5.3.2 Hesperetin and hesperetin conjugates evaluation 
  An external calibration curve for hesperetin aglycone, Hp3'Glu and 
Hp7Glu (prepared in 50% methanol, containing 0.2% ascorbic acid and 2.5 
µg/mL taxifolin) were generated across a concentration range of 41.6 nM to 
41.6 µM (see Figure 3.7). The LOQ was between 85-150 nM for Hp3'Glu 
and Hp7Glu, and below 40 nM for hesperetin. Each target-analyte area was 
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normalised to taxifolin as internal standard and results were transformed to 
log to provide linearity to all analytes.  
 
Figure ‎3.7 Logarithmic calibration curve for hesperetin, Hp7Glu and 
Hp3'Glu. The analysis was performed from 41.6 nM to 41.6 µM. 
  After these calibration curves were performed, it was found that 
Hp3'SO4 provided more signal than hesperetin aglycone. From a previous 
calibration (see 3.5.2.4) it was calculated that the MS signal for Hp3'SO4 was 
2.3x more than hesperetin aglycone (see Figure  3.5). Thus, 2.3 was used as 
a correction factor to calculate Hp3'SO4 excretion from urine samples.    
3.5.3.3 Urine analysis 
  Initially, extraction efficiency of each compound was calculated 
following the protocol above stated (see 3.4.4.5). It was found that each 
analyte (hesperetin, Hp7Glu and Hp3'Glu) yielded 66.9%, 80.7% and 76.8% 
respectively. A limited amount of Hp3'SO4 was available for accurate 
extraction test, so an estimated average extraction-efficiency of 74.8% was 
used after a one-time measurement. These values were used to adjust for 
analyte losses during sample handling. Samples were analysed in LC-
ESI/MS (see 3.4.4.7) and each metabolite was quantified using the 
calibration curves previously performed (see 3.5.3.2). A typical 
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chromatography of urinary metabolites excretion for each orange juice can 
be seen in Figure 3.8. 
 
Figure ‎3.8 TIC chromatograms of urine samples from one participant 
after metabolite extraction for all three orange juices. A) Freshly 
squeezed, B) premium brand and C) value brand. Metabolites 
identified: 1- Hp7Glu, retention time (RT)=7 min; 2- Hp3'Glu, RT=7.9 min 
and 3- Hp3'SO4, RT=8.1 min. Hp3'Glu and Hp3'SO4 were confidently 
identified following their negative mass-to-charge ratio (m/z 477, 381) 
and comparing them to their authentic standards.  
  A total of 2 volunteers were excluded from any analytical 
measurement as they did not provide complete urine sets. The remaining 
data was revised and those samples which showed metabolites in baseline 
urine and low or no excretion were discarded from statistical analysis. Thus, 
data from 10 volunteers was statistically analysed to determine if the 
ingestion of different commercial orange juices had an impact on hesperidin 
metabolism. Firstly, concentrations of metabolites excreted were corrected 
by the volume of orange juice ingested. Then, results were analysed as 
percentage of dose excreted in urine (see Table 3.1). 
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Table ‎3.1 Urinary excretion data and hesperidin ingested (mean values 
and standard deviations). 
 Freshly squeezed Premium brand Value brand 
N=10 Mean ± SD Mean ± SD Mean ± SD 
Hesperidin 
ingested (µmol) 
89.43 14.78 95.50 15.78 139.45 23.05 
Urinary excretion (% dose) 
Total metabolites 13.00 14.11 10.26 13.84 5.55 6.45 
Hp7Glu 1.57 2.01 1.36 1.86 0.56 0.41 
Hp3’Glu 10.04 10.58 7.84 10.38 4.41 5.30 
Hp3’SO4 1.40 1.60 1.06 1.63 0.58 0.76 
 The data was tested for normal distribution. Data for Hp7Glu, Hp3'Glu 
and Hp3'SO4 was not normally distributed, as determined by Shapiro-Wilk’s 
test (p < 0.05) (see Figure 3.9, A-C). In contrast, hesperidin ingestion was 
normally distributed, determined by Shapiro-Wilk’s test (p > 0.05) (see 
Figure 3.9, D).     
 
Figure ‎3.9 Histograms for data statistically analysed. Non-parametric 
data: A) Hp7Glu for three orange juices; B) Hp3'Glu for three orange 
juices; C) Hp3'SO4 for three orange juices. Parametric data: D) 
hesperidin ingested for three orange juices. J1- Freshly squeezed, J2 – 
premium brand and J3 – value brand. N=10 
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 A non-parametric analysis, the Friedman test, was used to determine 
if there was any significant difference in total metabolites excretion among 
the orange juices. The statistical results are showed in Table 3.2 and 
significant differences can be seen in Figure 3.10. 
 
Figure ‎3.10 Total metabolites excretion of each subject in the three 
orange juices. N=10, significance level is 0.05.    
  A statistical significant difference was found between total metabolite 
excretion and the three orange juices (p=0.0014). The post hoc analysis 
showed only a significant difference between total metabolite excretion from 
value brand orange juice to total metabolite excretion from freshly squeezed 
orange juice (p=0.011) where total metabolite excretion increased from 5.55 
± 6.45 % with value brand orange juice to 13.00 ± 14.11 %  with freshly 
squeezed orange juice.  
  In the same way, a Friedman test was used to determine if the 
significant difference between value brand and freshly squeezed orange 
juice was still valid in the samples without correction for Hp3'SO4 excretion. 
The statistical significant difference was still found in the three orange juices 
(p=0.007) and the post hoc analysis corroborated that total metabolite 
excretion was significantly different (p=0.005) between value brand orange 
Freshly squeezed Premium brand Value brand
0
5
10
15
20
25
30
35
40
45
50
55
p=0.011
P
e
rc
e
n
ta
g
e
 o
f 
d
o
s
e
 e
x
c
re
te
d
 i
n
 u
ri
n
e
 (
%
) 
- 57 - 
 
 
juice and freshly squeezed orange juice, as the excretion increased from 
6.30 ± 7.4% to 14.8 ± 16.2% respectively.  
Table ‎3.2 Statistical results from the non-parametric test Friedman to 
analyse significant difference within metabolites excreted and the three 
orange juices ingested. 
Parameter 
Chi-squared  distribution 
(X2-distribution) 
Degrees 
of 
freedom 
p value 
Hp7Glu excretion in 
three orange juices 
7.2 2 0.027 
Hp3’Glu excretion 
in three orange 
juices 
9.8 2 0.007 
Hp3’SO4  in three 
orange juices 
9.8 2 0.007 
Total metabolite 
excretion in three 
orange juices 
8.6 2 0.014 
   The analysis for each metabolite excretion in the three orange juices 
showed significant difference between value brand and freshly squeezed 
orange juice (see Figure 3.11), and the results can be seen in Table 3.2. 
Two outliers were identified and were not discarded from statistical analysis, 
as the concentration of metabolite excretion could have been affected by the 
nature of the study (crossover), the sample size (10 subjects) and the 
biological differences among the subjects (e.g. gut microflora) which should 
be taken into account.  
   It was found that percentage of Hp7Glu excretion was significantly 
different X2(2)=7.2, p=0.022 comparing freshly squeezed and value brand 
orange juices where the percentage increased from 0.56 ± 0.41% with value 
brand to 1.57 ± 2.00 % with freshly squeezed orange juice. As well, the 
percentage of Hp3’Glu excretion was significantly different X2(2)=9.8, 
p=0.005 between freshly squeezed and value brand orange where 
percentage increased from 4.41 ± 5.30% with value brand to 10.04 ± 10.56% 
with freshly squeezed orange juice. Finally, the percentage of Hp3’SO4 
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showed statistically significant difference X2(2)=9.8, p=0.007 between freshly 
squeezed and value brand orange juice where percentage increased from 
0.58 ± 0.76% with value brand to 1.40 ± 1.60% with freshly squeezed 
orange juice. No other relationships were significantly different.   
 
 
Figure ‎3.11 Percentage of dose excreted in urine by each subject in the 
three orange juices presented by urinary metabolite. A) Freshly 
squeezed, B) premium brand and C) value brand orange juice. N=10, 
significance level 0.05. 
    
  The data for hesperidin ingestion was normally distributed, as 
determined by Shapiro-Wilk’s test (p> 0.05) and is graphically shown in 
Figure 3.9, D. No outliers were found by inspection of a boxplot (see Figure 
3.12) 
 
- 59 - 
 
 
 
Figure ‎3.12 Hesperidin ingested by each subject in the three orange 
juices. N=10, significance level is 0.05. 
  As the data was normally distributed, a one-way repeated-
measurement ANOVA was conducted to determine the statistically 
significant difference in hesperidin consumption in the three orange juices. 
Results from within samples showed a statistically significant change of 
hesperidin ingested depending of which orange juice was drunk, F (1,9)=366, 
p<0.001. The post hoc analysis with a Bonferroni adjustment indicated that 
the amount of hesperidin consumed increased from 89.4 ± 14.8 µmol with 
freshly squeezed to 95.5 ± 15.8 µmol with premium brand and to 139.5 ± 
23.1 µmol value brand orange juice.  
 
3.6 Discussion 
  Hesperetin urinary-metabolites have been reported in the literature 
using different methodologies including enzymatic hydrolysis, specific mass-
to-charge ratios and NMR (Brett et al., 2009; Bredsdorff et al., 2010; Pereira-
Caro et al., 2014). Only a few publications have described the accurate 
identification and quantification of hesperetin urinary-metabolites using 
authentic standards. For example, Hp3'Glu and Hp7Glu have been 
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confidently identified by Brand et al. (2010) using true standards. They 
tested different glucuronosyltranferases and sulfotransferases from various 
sources (human and rat) as well as rat and human tissues to determine the 
kinetics for both biotransformations and explain the major hesperetin 
metabolites found in vivo. The identification of Hp3'SO4 was done by NMR 
analysis. Its quantification was done indirectly using the calibration curve at 
270 nm (UV range) for hesperetin and adjusting the results for the response 
factor 0.86. The sulfated form was collected, but not purified to obtain the 
authentic standard. Similarly, Pereira-Caro et al. (2014) identified Hp7Glu in 
urine samples after pulp-enriched orange juice consumption using a 
commercially-available standard (Extrasynthese, France). They also 
reported Hp3'Glu and Hp3'SO4 metabolites, but true standards were not 
used for their identification which was based on HPLC-MS2 fragmentation 
and previous information reported by Bredsdorff et al. (2010).  
  A common approach to avoid the use of authentic standards it is to 
assume that polyphenols (e.g. hesperetin) are glucuronidated and sulfated 
during phase II metabolism. Then, enzymatic hydrolysis using β-
glucuronidase and sulfatase will liberate the aglycones, which are most likely 
to be commercially-available, and quantification can be done indirectly using 
the calibration curve of the aglycone. Nevertheless, Saha et al. (2012) 
observed a lack of hydrolysis for epicatechin sulfates and methylepicatechin 
sulfates in urine samples after consuming two small chocolate bars. They 
treated their urine samples using standard hydrolysis conditions reported by 
other publications. Various modifications were applied to their protocol: 
increasing the quantity of enzyme, different incubation periods, pH 
optimisation and different commercially-available sulfatases were tested. 
Finally, they found that epicatechin sulfates and methylepicatechin sulfates 
remained in high quantities in the urine samples, assessed by their 
chromatography. They suggested that other reports have underestimated 
epicatechin content in biological fluids, as these metabolites are not 
efficiently hydrolysed enzymatically. In a similar way, Vallejo et al. (2010) 
found that  10% of hesperetin sulfate was unhydrolysed in urine samples 
after being treated with β-glucuronidase and sulfatase. Indeed, Charoensuk 
(2014) (unpublished) also found that sulfatase from Abalone entrails type 
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VIII was inhibited by unknown compounds in urine and did not hydrolyse 
quercetin and epicatechin sulfated from urine samples collected after 
ingestion of onion soup and dark chocolate by healthy volunteers.  
  The need for authentic standards was one of the main objectives to 
this research project. We modified a published protocol (see 3.4.2) to sulfate 
polyphenols and we introduced two different components: the use of pig liver 
cytosol (see 3.4.1) as main source of sulfotransferases and a co-cofactor for 
the reaction (PNS). Firstly, adding pig liver cytosol instead of human 
recombinant SULTs decreases the cost for the in vitro assay and makes 
more accessible the protocol. Secondly, PNS helps to increase 
transformation to sulfated forms. PNS was earlier reported by Koizumi et al. 
(1990) as a sulfate donor in the sulfation of quercetin using 
arylsulfotransferases isolated from human faeces. A year later, Koizumi et al. 
(1991) tested tannins and alkyl gallates  using the same protocol and they 
successfully sulfated these compounds, reporting up to 100% transformation 
for some of them. On the other hand, it was not until Tyapochkin et al. (2009) 
proposed a bypass mechanism where PAPS is regenerated by PNS after 
being used by the sulfotransferases (see Figure 3.13) that PNS was 
considered as a co-cofactor of the reaction and not only a sulfate donor. 
They tested their theory performing an activation assay using naphthol. They 
found that PNS intercepts PAP and converts it to PAPS immediately after it 
has been released, which later was used by naphthol to be converted to 
naphtyl sulfate. The result was explained as apparent ping-pong behaviour 
and supported their proposed mechanism. Our experiments showed that the 
addition of PNS into the mixture reaction increased the % transformation up 
to 40% changing from 38% without PNS to 80% with it (see 3.5.1). In 
addition, we showed that lower concentrations of PNS will work efficiently 
(see Figure 3.4) and will remain in less quantity in the mixture after the 
reaction has ended and a liquid-liquid extraction is performed.  
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Figure ‎3.13 Bypass mechanism proposed by Tyapochkin et al. (2009). 
PAPS is regenerated by PNS after being used by sulfotransferase in a 
ping-pong behaviour.   
  The biological synthesis of hesperetin provided us with Hp3'SO4, 
which has been reported to be one of the main urinary-hesperetin 
metabolites (Brett et al., 2009) and allowed to quantify accurately Hp3'SO4. 
Next, a cross-over human study was design with two major objectives: to 
quantify the main hesperetin urinary-metabolites and investigate the effect of 
type of orange juice consumed on the excretion of these metabolites. Urine 
samples were collected and analysed by Dr Tristan P. Dew and Miss 
Isabella Procopiou, and statistical analysis and interpretation was performed 
by this researcher.   
  First, the concentration of hesperidin (hesperetin glycoside) in two 
orange juices (freshly squeezed and premium brand, see Figure 3.6) was 
below what previous publications have reported (Manach et al., 2003; Brett 
et al., 2009). The variety of orange was not recorded, but the concentrations 
were similar to the amount found by Tomás-Barberán and Clifford (2000) for 
Navel orange juice (166-205 mg/L), and higher than the fresh and 
pasteurised fresh orange juice (47.2 ± 4.0 and 154.6 ± 47.2 mg/L 
respectively) by Silveira et al. (2014). The value-brand orange juice from 
concentrate showed similar hesperidin concentration (276 ± 21.6 mg/L) to 
those found by Erlund et al. (2001) and Brett et al. (2009), and it was higher 
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than those reported by Vallejo et al. (2010) for two commercial orange juices 
from concentrate (54-57 mg/L).  
  Most publications have reported the urinary excretion of hesperetin 
instead of its metabolites due to the lack of authentic standards. Our total 
metabolite excretion (Hp7Glu, Hp3'Glu and Hp3'SO4) was compared to 
aglycone results from different publications, assuming that if enzymatic 
hydrolysis was performed, the conjugates will be fully 100% transformed to 
their aglycone form (hesperetin). The values for freshly squeezed (13 ± 
14.1%) and premium brand (10.3 ± 13.8%) were higher from those 
reported by Manach et al. (2003) (4.1-6.4%), Nielsen et al. (2006) (low dose: 
4.1%, high dose: 8.9%), Brett et al. (2009) (4.5%) and Silveira et al. (2014) 
(3.8-4.1%). On the other hand, the urinary excretion reported by Nielsen et 
al. (2006) for their treated orange juice (14.4%) was slightly higher than our 
results. They explained this as an effect of the enzymatic conversion of 
hesperidin to hesperetin-7-O-glucoside which increased the bioavailability of 
the compound. The concentration reported by Krogholm et al. (2010) (13.9%) 
was similar to our result, even though the origin of their ‘juice mix’ was not 
reported. The total metabolite excretion for the value brand juice (5.6 ± 
6.5%) agreed with Erlund et al. (2001) (5.3%), Brett et al. (2009) (4.6%) and 
Vallejo et al. (2010) (orange juice A: 5.4%) values. The results reported by 
Pereira-Caro et al. (2014) (17.5%) cannot be confidently compared as the 
pulp-enriched orange juice was not identified as fresh or from concentrate 
orange juice. A summary of these results is shown in Table  3.3. 
Table ‎3.3 Urinary excretion (%) of hesperetin after hesperidin ingestion 
(juice) and its comparison with previous reports. 
Type of orange juice 
Total metabolite 
excretion (%) 
Reference 
Freshly squeezed  13 ± 14.1  Our report 
Premium brand 10.3 ± 13.8 Our report 
100% pure juice 4.1 ± 1.2 - 6.4 ± 1.3 Manach et al. (2003) 
Orange juice 
Orange juice enriched 
Orange juice treated  
4.1 ± 1.8 
8.9 ± 3.8 
14.4 ± 6.8 
Nielsen et al. (2006) 
- 64 - 
 
 
Orange fruit 4.5 ± 3.4 Brett et al. (2009) 
Processed orange juice 
OJ freshly squeezed 
4.1 ± 3.3 
3.8 ± 2.2 
Silveira et al. (2014) 
Juice mix 13.9 ± 8.7 Krogholm et al. (2010) 
Value brand 5.6 ± 6.5 Our report 
OJ from concentrate 5.3 ± 3.1 Erlund et al. (2001) 
OJ from concentrate 4.6 ± 3 Brett et al. (2009) 
OJ from concentrate (A) 
OJ from concentrate (B) 
5.4 ± 1.2 
1.7 ± 0.4 
Vallejo et al. (2010) 
Pulp-enriched OJ 
17.5 Pereira-Caro et al. 
(2014) 
OJ-Orange juice. 
  Further, we found a significant difference in the total metabolite 
excretion and the type of orange juice consumed (see Figure  3.10) and our 
results did not agree the previous report by Brett et al. (2009) who did not 
find any significant difference in the bioavailability of flavanones between 
fresh fruit and orange juice from concentrate. Their concentrations were 
calculated using enzymatic hydrolysis which can underestimate the real 
concentration of total urinary metabolites. Indeed, they suggested the 
appearance of metabolites Hp7Glu, Hp3'Glu and Hp3'SO4 relating their 
mass-to-charge ratio (LC-ESI/MS), UV spectra to each substitution site and 
confirming them by LC-MS2. No quantification was performed.  
  Following the report by Nielsen et al. (2006), their urine samples were 
further analysed by Bredsdorff et al. (2010). The metabolites were first 
identified on the basis of their MS spectra; then, their sites of conjugation 
were determined by NMR and isolated fractions were compared to authentic 
standards or diluted urine samples. They found < 1% urinary excretion for 
Hp7Glu for natural and fortified juice, and their results were below our report 
(1.6 and 1.4%, freshly squeezed and premium brand respectively). The 
excretion for Hp7Glu from the treated juice was approximately 1.5% and 
matched the value found for our freshly squeezed value. Hp3'Glu was 
excreted < 1.5% for natural juice,> 3.5% for the fortified juice and above 5% 
with their treated juice. Our results for freshly squeezed and premium brand 
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were above their findings (see Table 3.1) and only the value brand juice 
showed a concentration below 5%. Hp3'SO4 was < 1% for the natural and 
fortified juice, but above 1% for the treated juice. Our values for freshly 
squeezed and premium brand were < 1% and the excretion from value 
brand juice was around half the value (0.6 ± 0.8%). Our results are 
compared to their values graphically presented, as their precise 
concentrations were not reported in the text. These results and reported 
concentrations are shown in Table  3.4.  
  A recent publication for flavanone glycosides with a single dose of 
orange juice (fresh and pasteurised fresh orange juice) by Silveira et al. 
(2014) presented the quantification of Hp7Glu, Hp3'Glu and Hp3'SO4, but 
their results (Table 5 in published article) are presented without any 
specification of units and their interpretation is based in the differences (x-
fold) for each compound between both orange juices. Therefore, their 
concentrations and methodology are not discussed further. Finally, the 
report of orange juice polyphenols by Pereira-Caro et al. (2014) presented a 
quantification for hesperetin and naringenin metabolites. They used a pulp-
enriched orange juice, but did not identify the juice as fresh or from 
concentrate. Their metabolite identification was done following the specific 
mass-to-charge ratio for each metabolite in negative mode in a MS2 
methodology. Once the metabolites were identified, Hp7Glu was confirmed 
by the chromatography of its authentic standard, but Hp3'Glu and Hp3'SO4 
were only related to previous information published by Bredsdorff et al. 
(2010). Their reported value for Hp7Glu (1.4%, 4.7 ± 1.6µmol) was similar to 
our finding for the premium brand juice (1.4 ± 1.9%). The Hp7Glu excretion 
for freshly squeezed was above their value and the value brand juice was 
below it (see Table 3.1). They reported 5.5% (19.0 ± 6.5µmol) Hp3'Glu 
excretion which was again above the value for our value brand juice (4.4 ± 
5.3%), but below the data found for freshly squeezed and premium brand. In 
contrast, their concentration for Hp3'SO4 (5.2%, 18.2 ± 7.3µmol) was up to 
5x more than our report for all orange juices (see Table  3.4). This is due to 
the correction factor that we have applied to our measurements. We found 
that the signal in LC-ESI/MS of Hp3'SO4 was in average 2.3x more than 
hesperetin aglycone (see 3.5.2.4). 
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Table ‎3.4 A comparison of the urinary excretion of hesperetin 
metabolites (% dose) for different type of orange juices and their 
values reported in the literature. 
Metabolite 
Type of orange 
juice 
Urinary 
concentration  
(% dose) 
Reference 
H
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e
 Freshly squeezed 1.57 
Our study Premium brand 1.36 
Value brand 0.56 
Natural juice < 1 
Bredsdorff et al. 
(2010) 
Treated juice approx. 1.5 
Fortified juice < 1 
Pulp-enriched juice 1.35 
Pereira-Caro et 
al. (2014) 
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 Freshly squeezed 10.04 
Our study Premium brand 7.84 
Value brand 4.41 
Natural juice < 1.5 
Bredsdorff et al. 
(2010) 
Treated juice above 5 
Fortified juice > 3.5 
Pulp-enriched juice 5.46 
Pereira-Caro et 
al. (2014) 
H
e
s
p
e
re
ti
n
-3
'-
O
-s
u
lf
a
te
 
Freshly squeezed 1.40 
Our study Premium brand 1.63 
Value brand 0.58 
Natural juice < 1 
Bredsdorff et al. 
(2010) 
Treated juice above 1 
Fortified juice < 1 
Pulp-enriched juice 5.23 
Pereira-Caro et 
al. (2014) 
 
  This phenomenon was also reported by Farrell et al. (2011) who 
found higher signal measuring hydroxycinnamic acids glucuronide and 
sulfate by LC-ESI/MS2. They found a response of 3 to 10x higher from 
- 67 - 
 
 
metabolites compared to their aglycones. Also, Brand et al. (2010) used a 
correction factor of 0.86 to quantify Hp3'SO4 produced after an in vitro assay 
using human and rat sulfotransferases. Their quantification was done using 
the calibration curve of hesperetin which was measured by HPLC-DAD. 
Therefore, as Pereira-Caro et al. (2014) are not using authentic standards 
for the quantification of Hp3'SO4 and their measurements do not take into 
account the MS response of the sulfated form, this value might not reflect 
the real concentration of Hp3'SO4 present in the urine samples.  
  In conclusion, to our knowledge, this is the first report showing the 
synergy between PAPS and PNS for the biological sulfation of polyphenols, 
obtaining a metabolite found in in vivo conditions. This methodology can 
lead to availability of Hp3'SO4 as authentic standard which we have shown 
with the quantification of Hp7Glu, Hp3'Glu and Hp3'SO4. It is important to 
address that enzymatic hydrolysis can provide general information about the 
metabolism of hesperetin or other polyphenols, but it will not help to identify 
and quantify accurately the metabolites produced in vivo.   
  
- 68 - 
 
 
CHAPTER 4  Selective inhibition of COX-2 by plant extracts 
and their unconjugated and conjugated polyphenols  
 
4.1 Abstract 
   Cyclooxygenase 2 (COX-2) is an enzyme responsible for the 
conversion of arachidonic acid to prostanoids (e.g. PGH2, PGE2) which have 
been related to inflammatory diseases, and its inhibition has become the 
main goal for research. Plant extracts and their main polyphenols 
(unconjugated and conjugated) have become an alternative to drug 
therapies, but their behaviour is still not well understood. This project aimed 
to find the inhibition of recombinant human COX-2 by different plant extracts 
and a series of unconjugated and conjugated polyphenols. Two procedures 
were used to measure the % inhibition by the different analytes. Firstly, a 
COX inhibitor screening assay was used to quantify, via enzyme 
immunoassay (EIA), PGF2α which is a reduced form of PGH2. Green tea (0.1 
mg/mL) and German chamomile (0.5 mg/mL) showed more than 75% 
inhibition of recombinant human COX-2, and following tests with 
unconjugated and conjugated polyphenols provided no consistent results. 
Next, a mass spectrometry method was used to quantify directly PGE2. 
Unconjugated and conjugated polyphenols showed inhibition, but their 
results were not reproducible. Green tea (GT) was the only plant extract that 
showed coherent results and presented concentration dependence. It was 
found that GT IC50 for COX-2 was 16.1 µg/mL. Lastly, the two main GT 
polyphenols epigallocatechin gallate (EGCG) and epigallocatechin (EGC) 
were tested and both showed concentration dependence. Subsequently, 
their IC50 were calculated at 2.8 and 9.2 µM respectively. So far, no 
publications have shown the inhibition of recombinant human COX-2 by 
green tea, as other research has focused on effects on enzyme expression 
or other pro-inflammatory cytokines.  
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4.2 Introduction 
   Chronic inflammation appears to be associated with the malfunction 
of tissue, producing imbalance in the physiological systems that are not 
directly functionally related to host defence or tissue repair (Medzhitov, 
2008). During chronic inflammation, pro-inflammatory enzymes are secreted 
in large amounts to eliminate foreign pathogens, but they also attack normal 
tissues which lead to cell damage (Pan et al., 2009).     
  Pro-inflammatory enzymes, such as cyclooxygenase enzymes, 
convert polyunsaturated fatty acids (PUFA) into lipid mediators (eicosanoids). 
There are two main cyclooxygenase enzymes: COX-1 is normally present in 
most tissues and it is involved in essential maintenance necessary for 
normal physiological activity whereas COX-2 is the inducible form which is 
produced in response to inflammation and it is usually undetectable in 
healthy tissues (Stables and Gilroy, 2011; Cao et al., 2011).  
  COX-2 has become an important target to battle against inflammatory 
conditions as atherosclerosis, arthritis and various types of cancer (Raman 
et al., 2008). Selective inhibitors of COX-2, e.g. celecoxib, rofecoxib and 
others have been developed and historically used for the treatment of 
chronic inflammatory conditions. However, these drugs have been recently 
associated with an increase in blood pressure, myocardial infarction, or 
stroke (Raman et al., 2008; Salvado et al., 2012). Thus, researchers have 
started to seek for alternatives which can effectively inhibit COX-2 and 
provide less or no side effects.  
  Plant extracts and natural compounds isolated from them are the 
main focus for potential bioactive molecules. For instance, catechins and 
flavonoids from green tea have been related to decrease COX-2 expression 
and NF-κB activation (Peng et al., 2006; Aggarwal and Shishodia, 2006). 
NF-κB is a nuclear factor that activated induces cellular transformation, 
proliferation, cellular differentiation, chemo-resistance, and inflammation 
(Golan-Goldhirsh and Gopas, 2014). Apigenin and luteolin from German 
chamomile also inhibit NF-κB activation pathway and German chamomile 
extract reduced COX-2 mRNA in RAW 264.7 cells (Aggarwal and Shishodia, 
2006; Srivastava et al., 2009). Ginsenoside Rd from ginseng inhibited COX-
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2 expression in RAW 264.7 cells and supressed PGE2 production in 
stimulated RAW 264.7 cells (Kim et al., 2013). Gingko biloba showed anti-
inflammatory activity in ANA-1 cells inhibiting inflammatory markers as iNOS, 
TNF-α and COX-2 (Kotakadi et al., 2008). Similarly, Cucurbita ficifolia has 
been tested in induced type-2-diabetes mice and the treatment with an 
aqueous fraction proved to decrease the pro-inflammatory cytokine TNF-α, 
but increased other cytokines such as IL-6 and IFN-γ (Roman-Ramos et al., 
2012). Despite the scientific research on plant extracts, experimental 
information is still scarce and more analyses are needed.  
  Diverse techniques to test the anti-inflammatory activity of plant 
extracts are used. The most common are animal and cell culture models 
which can be employed along with spectrophotometry or spectrometry 
methodologies. Recently, mass spectrometry has become a powerful 
alternative to identify and quantify compounds. One of its main advantages 
is the selectivity to target analytes, e.g. PGE2 which contribute to faster 
analysis and validated results (Cao et al., 2011; Zhu et al., 2014). This 
research project examines the inhibitory activity of various plant extracts and 
their main polyphenols (unconjugated and conjugated) using two different 
techniques: spectrophotometric analysis by immunoassay test and mass 
spectrometry (LC-ESI/MS) by in vitro assay. According to our recent search, 
there is no report in the literature that compares these plant extracts and 
polyphenols for their recombinant human COX-2 inhibition.   
4.3 Materials 
Hesperetin, myricetin, galangin and naringenin were purchased from 
Extrasynthese (Genay Cedex, France); quercetin, baicalein, celecoxib, 
kaempferol-3-O-β-glucuronide (K3glu), 20(S)-protopanaxatriol (PPX), 
epigallocatechin gallate (EGCG), epigallocatechin (EGC), epicatechin gallate 
(ECG) and epicatechin (EC) were purchased from Sigma-Aldrich (Dorset, 
UK). Hesperetin-3'-O-glucuronide (Hp3'glu) and hesperetin-7-O-glucuronide 
(Hp7glu) were kindly provided by Professor Denis Barron (Nestle, 
Switzerland).  Apigenin, luteolin, umbelliferone, bilobalide, ginkgolides (A, B, 
C and J) and ginsenosides (C-K, Rb1, Rb2, Rb3, Rc, Rd, Re, Rf, Rg1, Rg2, 
Rg3, Rh1 and Rh2), as German chamomile (GC) (Matricaria recutita) and 
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green tea (GT) (Camellia sinensis) were bought or provided by PhytoLab as 
part of PlantLIBRA project. Gingko powder (Gingko biloba) was bought from 
Indigo Herbs (Glastonbury, UK). Ginseng Korean root powder (ginseng) 
(Panax ginseng) was bought from G Baldwin & Co. (London, UK). 
Quercetin-3'-O-sulfate (Q3'SO4) was prepared enzymatically and provided 
by Dr. C.C. Wong. Hesperetin-3'-O-sulfate (Hp3'SO4) was kindly provided by 
Dr. C. Monrad (INRA, France). Chilacayote extract (cucurbita) (Cucurbita 
ficifolia) was provided by Dr. F.J. Alarcon-Aguilar (UAM-I, Mexico). Trans-
resveratrol (Resveratrol), COX inhibitor screening assay kit and human 
recombinant COX-2 were purchased from Cayman Chemical (Cambridge, 
UK). All water refers to deionised Millipore water (Hertfordshire, UK) unless 
otherwise stated. 
     
4.4 Methods 
4.4.1 COX inhibition assay testing different polyphenols and plant extracts 
 The effect of quercetin, hesperetin, cucurbita, GC, GT and other 
compounds on production of PGF2α was tested using a COX inhibitor 
screening assay kit which measures directly PGF2α via enzyme 
immunoassay (EIA). The pathway from arachidonic acid to PGF2α can be 
seen in Figure 4.1. The assay is based on the competitive reaction between 
prostaglandins and an acetylcholinesterase conjugate (PG tracer) to bind a 
limited amount of prostaglandin antiserum. The amount of PG tracer is 
constant, so the concentration of PGF2α produced will be inversely 
proportional to the absorbance measured. The quantification is achieved by 
measuring the activity of the acetylcholinesterase using acetylthiocholine 
and Ellman’s reagent. The product absorbs strongly at 412nm, but it can be 
detected from 405 to 420 nm. The schematic reaction can be seen in Figure 
4.2.    
  Each test followed the manufacturer’s protocol and used reagents 
provided by it. Concisely, reaction buffer (0.1 M Tris-HCl, pH 8.0, containing 
5 mM EDTA and 2 mM phenol), heme ( Tris-HCl, pH 8.0), enzyme (COX-2) 
and inhibitor were mixed in an Eppendorf tube and incubated for 10 min at 
37°C. Then, the reaction was initiated adding arachidonic acid, followed by 2 
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min incubation at the same temperature. HCl was added to stop the reaction. 
Samples with or without stannous chloride were performed. 
 
Figure ‎4.1 Schematic pathway of prostaglandin biosynthesis from 
arachidonic acid via COX-2 to  PGF2α. 
  Afterwards, a 96-well plate was set and the binding reaction was 
developed up to 18 hrs in the dark, with orbital shaking (100 rpm) and at 
room temperature (25°C). Resveratrol (30 µM) and celecoxib (1 µM) were 
used as positive controls. After 18 hrs, the plate was developed using 
Ellman’s reagent  (5,5'-dithiobis-(2-nitrobenzoic acid), DTNB) and incubated 
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in the dark during 60 to 90 minutes with constant orbital shaking (100 rpm). 
All samples were read in a PHERAstar FS microplate reader set at 410 nm. 
Results were analysed using a 4-parameter logistic fit, calculated through 
myassays.com and interpreted using Microsoft Excel (2010). 
 
Figure ‎4.2 Schematic reaction between acetylthiocholine and Ellman's 
reagent to quantify the activity of acetylcholinesterase present after 
EIA. The product (5-thio-2-nitrobenzoic acid) is detected from 405 to 
420 nm. Modified from COX inhibitor screening assay kit booklet 
(Cayman Chemical). 
 
4.4.2 Cyclooxygenase inhibition measuring PGE2 by LC-ESI/MS using 
solvent extraction. 
 Different plant extracts, conjugated and unconjugated polyphenols 
were tested for inhibition of COX-2 human recombinant, using a modified 
method by Cao et al. (2011). Reactions were performed in Eppendorf tubes 
using 146 µL of 100 mM Tris-HCl (pH 8.0) buffer, 2 µL of 100 µM hematin 
and 10 µL of 40 mM L-epinephrine which were mixed at room temperature. 
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Then, 20 µL of recombinant human COX-2 (0.2-0.8 µg) diluted in Tris-HCl 
(pH 8.0) was added, and the mix was incubated at 25°C for 2-4 min. A 2 µL 
aliquot of inhibitor was added to the solution and pre-incubated for 10 min at 
37°C in a water bath. Controls were carried out at the same time, 
substituting enzyme or inhibitor or both by Tris-HCl (pH 8.0) buffer. 
 The reaction was initiated by adding 20 µL of arachidonic acid in Tris-
HCl (pH 8.0) to obtain a final concentration of 5 µM. After 2 or 4 min, the 
reaction was finished by adding 20 µL of 2.0 M HCl. Shortly, the surrogate 
standard d4-PGE2 was added (10 µL, 2.8 µM) to correct for any errors during 
liquid-liquid extraction. The solutions were incubated at 25°C for 30 min with 
constant orbital shaking (130 rpm). Next, PGE2 and surrogate were 
extracted from each incubated mixture using 800 µL hexane/ethyl acetate 
(50:50,v/v). Samples were manually shaked for 1 min and vortex sideways 
for 30 sec to assure that both layers were mixed. Then, after 5 min 
ultracentrifuge (17,000 g, room temperature), the organic layer was removed 
and evaporated under vacuum (Genevac, EZ-2 plus model; Fisher Scientific 
Ltd., Leicestershire, UK) using a low BP mixture program without heat (lamp 
off).  Samples were reconstituted with 100 µL methanol/water (50:50,v/v) 
and analysed using a Shimadzu LC-2010 HT coupled with a LCMS-2020 
quadrupole mass spectrometer fitted with an electro spray ionisation source 
(Milton Keys, UK). A Waters XTerra MS C18 (2.1x50 mm, 3.5 µm) analytical 
column was used to perform the separation and was maintained at 35°C. 
The injection volume was 10 µL and the flow rate was set at 0.2 mL/min. The 
solvent A consisted of a mix of acetonitrile:water (35:65, v/v) with 0.1% 
formic acid and samples were run under an isocratic method. PGE2 and its 
surrogate (d4-PGE2) were identified following their mass-to-charge ratio in 
negative mode (m/z 351,355 respectively). Those samples that were not 
immediately analysed were kept at -20°C until further analysis.  
  Statistical analyses were performed using IBM SPSS statistics 22 
(Portsmouth, UK). Data was assessed to determine normality by Shapiro-
Wilk’s and a within-within-subjects ANOVA was conducted for data normally 
distributed. Significance level was determined as p<0.05. 
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4.5 Results 
4.5.1 Measurement of prostaglandins by spectrophotometer using a 
screening assay. 
 Firstly, hesperetin and quercetin were measured (see Figure  4.3) at 
different concentrations, adding or not the reducing agent stannous chloride 
(SnCl2). This test provided information about the capacity of the natural 
reductase to transform PGH2 into PGF2α and the efficacy of the positive 
controls. Hesperetin (5 µM) showed 24% inhibition and resveratrol and 
celecoxib (positive controls) showed 80% and 87% respectively. These 
values were calculated assuming 100% activity for no inhibitor samples. An 
independent t-test was used to determine the statistical difference between 
the control (no inhibitor) and samples with SnCl2. It was found that 
hesperetin 5 µM was statistically different from the inhibitor (p=0.0292) as 
well as resveratrol (p=0.016) and celecoxib (p=0.0019).   
 
Figure ‎4.3 Measurement of PGF2α to calculate COX-2 inhibition by 
unconjugated polyphenols. Resveratrol and celecoxib were used as 
positive controls. N=2 biological replicates, 1 technical measurement, ± 
SD. Asterix (*) represents statistical difference.  
Then, various plant extracts were tested (see Figure 4.4) at 0.1 and 1 
mg/mL adding stannous chloride. The final concentration of GC was 
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corrected for its 50% maltodextrin content. From these, GT (0.1 mg/mL) and 
GC (0.5 mg/mL) provided more than 75% inhibition. Indeed, an independent 
t-test showed that GT (0.1 mg/mL) and GC (0.5 mg/mL) were statistically 
different (p= 0.0056 and p=0.0074 respectively) from the control (no 
inhibitior), as well as resveratrol and celecoxib (see values above).   
 
Figure ‎4.4 Measurement of PGF2α to calculate COX-2 inhibition by 
different plant extracts. Resveratrol (30 µM) and celecoxib (1 µM) were 
used as positive controls. N=2 biological replicates, 1 technical 
measurement, ± SD. Asterix (*) represents statistical difference.  
  After the preliminary tests were done, several unconjugated and 
conjugated polyphenols were analysed (see Figure 4.5 and Table 4.1) to find 
those compounds which inhibit COX-2 activity. These compounds were 
chosen for their presence in the plant extracts and suggested health benefit 
reported by literature. All were tested at 5 µM concentration.  
As a result, quercetin, apigenin, gingkolide J, ginsenoside Rg1, 
Hp3'SO4, K3Glu, ginsenoside Re, Rf, Rd, kaempferol, ginsenoside Rg3 and 
Rh1 showed more than 25% inhibition. Then, these compounds were tested 
in further analysis. Statistical analysis (t-test) did not show any statistically 
significant difference between control (no inhibitor) and samples.   
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Figure ‎4.5 Measurement of PGF2α to calculate COX-2 inhibition by various unconjugated and conjugated polyphenols. 
Compounds were tested at 5 µM except positive controls. Samples: 1- No inhibitor, 2-celecoxib (1µM), 3-resveratrol (30 µM), 
4-apigenin, 5-luteolin, 6-baicalein, 7-myricetin, 8-quecetin, 9-kaempferol, 10-galangin, 11-hesperetin, 12-naringenin, 13-
umbelliferone; gingkolides: 14-A, 15-B, 16-C and 17-J; ginsenosides: 18-C-K, 19-Rb1, 20-Rb2, 21-Rb3, 22-Rc, 23-Rd, 24-Re, 
25-Rf, 26-Rg1, 27-Rg2, 28-Rg3, 29-Rh1 and 30-Rh2; 31-bilobalide, 32-Q3'SO4, 33-Hp3'SO4 and 34-K3glu.  N=2 biological 
replicates, 1 technical measurement, ± SD.   
 
- 7
7
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Table ‎4.1 Measurement of PGF2α and calculated COX-2 inhibition of  
various unconjugated and conjugated polyphenols. Compounds were 
tested at 5 µM. N=2 biological replicates, 1 technical measurement.  
Compound PGF2α (pg/mL) ± SD Inhibition (%) 
Apigenin 737486 19499 30 
Luteolin 1085403 243177 0 
Baicalein 1027230 88122 2 
Myricetin 820266 246552 22 
Quercetin 756932 6011 28 
Kaempferol 562220 203820 46 
Galangin 922991 3698 12 
Hesperetin 940270 145168 10 
Naringenin 928185 156667 11 
Umbelliferone 941181 72889 10 
Gingkolide A 1355383 337331 0 
Gingkolide B 1099976 246596 0 
Gingkolide C 829517 145819 21 
Gingkolide J 641232 238343 39 
Bilobalide 788854 304371 25 
Ginsenoside C-K 764144 158650 27 
Ginsenoside Rb1 701859 17592 33 
Ginsenoside Rb2 766448 132270 27 
Ginsenoside Rb3 721991 117701 31 
Ginsenoside Rc 1089860 367803 0 
Ginsenoside Rd 572448 318552 45 
Ginsenoside Re 582684 84359 44 
Ginsenoside Rf 578948 48434 45 
Ginsenoside Rg1 615319 373800 41 
Ginsenoside Rg2 740595 168831 29 
Ginsenoside Rg3 561421 92753 46 
Ginsenoside Rh1 515738 95499 51 
Q3'SO4 858580 77600 18 
Hp3'SO4 692369 51985 34 
K3Glu 614102 28188 41 
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  Firstly, hesperetin and three conjugates (Hp3'glu, Hp7glu and 
Hp3'SO4) were used to explore concentration dependence for COX-2 
inhibition. Compounds were tested from 1 to 5 µM, using celecoxib (1 µM) 
as positive control (see Figure  4.6 ).          
 
Figure ‎4.6 Measurement of PGF2α to calculate COX-2 inhibition by 
hesperetin and hesperetin conjugates. Samples: 1-No inhibitor, 2-
celecoxib (1 µM), hesperetin: 3- 1 µM, 4- 2 µM, 5- 3 µM, 6- 5 µM; Hp7glu: 
7- 1 µM, 8- 2 µM, 9- 3 µM, 10- 5 µM; Hp3'glu: 11- 1 µM, 12- 2 µM, 13- 3 
µM, 14- 5 µM and Hp3'SO4: 15- 1 µM, 16- 2 µM, 17- 3 µM, 18- 5 µM. N=3 
biological replicates, 1 technical measurement, ±SD. 
  Consequently, the inhibition was lower than previously observed for 
those compounds that were tested again. For instance, hesperetin (5 µM) 
inhibited 10% during the first screening, but showed 40% inhibition in the 
second test. On the other hand, the opposite effect was observed for 
Hp3'SO4 (5 µM) which presented 41% in the first measurement and no 
inhibition in the second screening. An independent t-test showed that 
samples were not statistically different from the control (no inhibitor).  
 Thus, different modifications were made to the manufacturer’s 
protocol. Initially, in vitro reactions were performed using kaempferol, K3glu 
and different ginsenosides (Re, Rg1, Rg2, Rh1 and PPX). The protocol 
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stated a 2000x dilution for each sample to be used in the EIA assay. So, 
samples following the protocol were used to develop the EIA assay and a 
4000x dilution was also tested (data not shown). Next, only ginsenoside Rg1 
and PPX (both 4000x dilution) showed 20% and 46% inhibition respectively. 
Celecoxib (1 µM) measurement was out of the standard values and could 
not be quantified.  
 Then, assays using different dilutions factors were performed using 
250x, 500x, 1000x and 8000x dilution. For this effect, celecoxib (1 µM) and 
ginsenoside Re (5 µM) were used as testing compounds. Re (250x dilution) 
presented 45% inhibition, but other dilutions could not be quantified, as their 
measurements were out of the standard curve range.  
  Finally, two other dilutions were performed (100x and 200x) which 
represented samples 10x and 20x less diluted from the manufacturer’s 
recommendation. Ginsenosides (Re, Rg1, Rg2, Rh1 and PPX) at 5 µM were 
tested, using celecoxib (5 µM) as positive control (see Figure  4.7). In both 
dilutions, celecoxib showed more than 80% inhibition. 
 
Figure ‎4.7 Measurement of PGF2α to calculate COX-2 inhibition by 
ginsenosides. Samples: 1- No inhibitor, 2- celecoxib; ginsenosides: 3- 
Re, 4- Rg1, 5- Rg2, 6- Rh1 and 7- PPX. All compounds were tested at 5 
µM. N=2 biological replicates, 1 technical measurement, ± SD. Asterix 
(*) represents statistical difference.  
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  At 100x dilution, Re and PPX showed 25% and 55% inhibition 
respectively whereas celecoxib and Rh1 presented 82% and 20% each. On 
the other hand, at 200x dilution, the value for celecoxib and Rh1 increased 
up to 87% and 31%, but decreased for Re and PPX (14% and 34% 
respectively). An independent t-test showed that celecoxib at 100x and 200x 
was statistically different (p=0.0172 and p=0.0041 respectively) to the control 
(no inhibitior). Rh1 at 200x was statistically different from the control 
(p=0.0279) and PPX at both dilutions was also statistically different 
(p=0.0336 and p=0.0410 respectively) to the control.  
  Finally, it was decided to not further analyse any compounds using 
this methodology due to its unpredictable variation and the discrepancy of 
results. Therefore, an LC-MS assay was carried out to test those 
compounds with potential recombinant human COX-2 inhibition.  
4.5.2 PGE2 quantification by LC-ESI/MS using an in vitro assay and solvent 
extraction. 
  A series of plan extracts, conjugates and unconjugated polyphenols 
were tested and quantified using the methodology described above (see 
4.4.2). This in vitro assay provided more selective measurement of PGE2 
and faster analysis than the immunoassay previously used.  
  The concentration of PGE2 produced during the in vitro test was 
calculated using a PGE2 calibration curve from 1.41 to 10.58 ng (40 nM to 3 
µM respectively) (see Figure 4.8). The limit of detection (LOD) was 0.07 ng 
and the limit of quantification (LOQ) was 0.22 ng. These values were 
calculated using the equation LOD=(SD/slope)*3 and LOQ=(SD/slope)*10. 
The d4-PGE2 surrogate was used to correct any losses during solvent 
extraction; its LOD and LOQ were 0.09 ng and 0.29 ng respectively. A 
calibration curve was also performed for d4-PGE2, but it was found that after 
the liquid-liquid extraction the MS signal of the surrogate was enhanced. 
Then, the correction was done using the absolute intensity from a 0.43 ng 
sample which followed the same protocol, but without inhibitor. A typical 
chromatogram of both standards can be seen in Figure 4.9.  
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Figure ‎4.8 Calibration curve for PGE2 using a commercially available 
standard diluted in methanol:water (50:50, v/v) at a high concentration 
and further diluted to various concentrations. N=3 biological replicates 
and 1 technical measurement. 
 
Figure ‎4.9 Example of selected ion monitoring (SIM) chromatography 
(LC-ESI/MS) showing the standards PGE2 (m/z 351) and d4-PGE2 (m/z 
351). Each was separately measured using a 10 µL aliquot of 0.7 µM 
solution (2.47 and 2.50 ng respectively).  
4.5.2.1 In vitro assay method optimisation 
  The protocol published by Cao et al. (2011) suggested the use of 0.1-
0.2 µg of protein (approximately 1 unit of  recombinant human COX-2) and 2 
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min incubation for the in vitro assay. Consequently, the first test was to 
assess the impact of COX-2 concentration in the assay. This was done by 
performing the assay at two different COX-2 concentrations (0.2 and 2 µg). 
Firstly, samples (with/without inhibitor) at 0.2 µg did not provide with any 
PGE2 signal in LC-ESI/MS. Samples at 2 µg did provide PGE2 signal in LC-
ESI/MS and their chromatograms can be seen in Figure  4.10.  
 
Figure ‎4.10 Typical MS chromatogram for the total ion counting (TIC) of 
sample without and with inhibitor (celecoxib 5 µM). The peak 1 is PGE2 
and 2 is PGD2.  
  Next, lower concentrations (0.4 and 0.8 µg) and different incubation 
times were tested (seen Figure 4.11). The samples were developed without 
inhibitor and a statistical analysis (ANOVA) was performed. The data was 
normally distributed, as assessed by Shapiro-Wilk test (p>0.05) for all 
samples. It was found a statistically significant difference between 
treatments (p=0.001) where the amount of PGE2 increased from 1.4 ± 0.2 ng 
with 0.4 µg COX-2 to 4.5 ± 0.6 ng with 0.8 µg COX-2. This difference was 
reflected in the signal registered during LC-ESI/MS analysis. The absolute 
intensity was higher which reduced the effect of background noise (see 
Figure 4.12). 
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Figure ‎4.11 PGE2 concentration of samples at two different enzyme 
concentrations (COX-2). Asterix (*) indicates those samples 
statistically significant different (p<0.05).   
  In addition, the three incubation times for each treatment were 
compared. Samples using 0.4 µg COX-2 were statistically significant 
different (p=0.003). Post hoc analysis with a Bonferroni adjustment revealed 
that the difference in PGE2 concentration was from 1 ± 0.03 ng with 2 min to 
1.7 ± 0.04 ng at 4 min (p=0.032). Equally, samples using 0.8 µg COX-2 were 
statistically significant different (p=0.002) and a post hoc analysis with a 
Bonferroni adjustment showed that PGE2 concentration differed from 3.2 ± 
0.20 ng at 2 min to 4.6 ± 0.17 ng at 3 min.   
  Eventually, 0.8 µg was chosen to perform the in vitro assay and two 
minutes remain as the incubation time. Even though statistically significant 
difference was found at times 2 and 3 min for 0.8 µg these reactions did not 
include inhibitor. Cao et al. (2011), concluded that the production of PGE2 
was linear up to 2 min (using different COX inhibitors); hence experiments at 
2 and 4 min incubation were performed using 0.8 µg. Celecoxib (5 µM) was 
used as positive control to guarantee the activity of COX-2 and its inhibitory  
activity determined the time to use for further experiments. Samples at 4 min 
showed up to 52% inhibition (data not shown) and samples at 2 min 
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provided up to 85% inhibition (see 4.5.2.2). Further experiments were 
performed using 0.8 µg COX-2 human recombinant and 2 min incubation. 
 
Figure ‎4.12 MS chromatograms for samples with different COX-2 
concentration and at different incubation times. Samples A2, A3 and 
A4 show 0.4 µg samples and each number represent the min of 
incubation. Similarly, samples B2, B3 and B4 represent 0.8 µg samples. 
PGE2 is arrow 1 and PGD2 is arrow 2. The chromatograms are the 
mass-to-charge ratio for the specific compounds PGE2 and d4-PGE2 
(m/z 351 and 355).    
  
4.5.2.2 COX-2 inhibition by plant extracts and their major polyphenols 
  Plant extracts were tested at 0.1 and 1 mg/mL concentrations (see 
Figure 4.13 – A). Conjugated and unconjugated (aglycones) polyphenols 
were tested at 5 µM (see Figure 4.13- B and C) and ginsenosides (see 
Figure 4.13- D) were also tested at 5 µM. For each experiment a control (no 
inhibitor, no enzyme), a 100% activity (no inhibitor) and a positive control 
(celexoxib, 5 µM) were tested alongside inhibitors. 
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Figure ‎4.13 Percentage of inhibition and PGE2 concentration for 
various compounds. Plant extracts (A): 1-GT 0.1 mg/mL, 2-GT 1 mg/mL, 
3- GC 0.1 mg/mL, 4- GC 1 mg/mL, 5- cucurbita 0.1 mg/mL, 6- cucurbita 
1 mg/mL, 7- gingko 0.1 mg/mL, 8- gingko 1 mg/mL, 9- ginseng 0.1 
mg/mL and 10- ginseng 1 mg/mL. Unconjugates (B): 11- quercetin, 12-
kaempferol and 13-hesperetin. Conjugates (C): 14- Hp3'SO4, 15- 
Hp3'Glu, 16- Hp7Glu, 17- K3Glu and 18- Q3'SO4. Ginsenosides (D): 19- 
Re, 20- Rh1, 21- Rg1, 22- Rg2 and 23- PPX. Compounds showed in 
graphs B, C and D were tested at 5 µM. Celecoxib (5 µM) was used as 
positive control and inhibited more than 75% (data not shown). N=3 
biological replicates and 1 technical measurement, ± SD. 
  The first analysis showed that all plant extracts inhibit COX-2 more 
than 60% at 1 mg/mL and indicated that inhibition decreased at lower 
concentrations (0.1 mg/mL). The highest COX-2 inhibition was produced by 
GT (98%, 1 mg/mL), followed by GC (86%, 1 mg/mL). Quercetin and 
kaempferol were more efficient COX-2 inhibitors than their conjugates 
(Q3'SO4 and K3Glu) with more than 45% inhibition. In contrast, hesperetin 
conjugates (Hp3'SO4, Hp3'Glu and Hp7Glu) inhibited COX-2 from 25 to 55% 
meanwhile hesperetin aglycone inhibited only up to 21%. Ginsenosides 
inhibited from a range of 12 to 51%. The best inhibitor was Rg1 (50%) and 
the weakest was Re (12%).  
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  Afterwards, conjugates, aglycones and ginsenosides were tested at 
three different concentrations (1, 5 and 10 µM) to seek for concentration 
dependence. First, quercetin, kaempferol and hesperetin were analysed 
(see Figure 4.14) at 1, 5 and 10 µM. Samples at 5 µM did not agree with 
previous results where quercetin at 5 µM inhibited 49% (see Figure 4.13)  
and after the second test decreased up to 18%. A similar phenomenon was 
observed among the others. For instance, kaempferol inhibited COX-2 in 
49% during the first test and it did not show any inhibition after the second 
assay. On the contrary, the COX-2 inhibition increased for hesperetin (5 µM) 
up to 35% which was 10% difference from the first test.   
  
Figure ‎4.14 Percentage of inhibition and PGE2 concentration for 
unconjugated polyphenols. Samples → quercetin: Q1- 1 µM, Q2- 5 µM 
and Q3- 10 µM; kaempferol: K1- 1 µM, K2- 5 µM and K3- 10 µM; 
hesperetin: Hp1- 1 µM, Hp2- 5 µM and Hp3- 10 µM. Celecoxib (5 µM) was 
used as positive control and inhibited more than 60% (data not shown). 
N=3 biological replicates and 1 technical measurement, ± SD. 
   Later, conjugates from quercetin, kaempferol and hesperetin were 
tested (see Figure 4.15). The conjugates used were Q3'SO4, K3Glu, 
Hp3'SO4, Hp3'Glu and Hp7Glu. The inhibitors were analysed at the same 
concentrations as their unconjugated forms were tested.  
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Figure ‎4.15 Percentage of inhibition and PGE2 concentration for 
conjugated polyphenols. Samples →‎Q3'SO4: 1- 1 µM, 2- 5 µM and 3- 10 
µM; K3Glu: 4- 1 µM, 5- 5 µM and 6- 10 µM; Hp3'SO4: 7- 1 µM, 8- 5 µM and 
9- 10 µM; Hp3'Glu: 10- 1 µM, 11- 5 µM and 12- 10 µM; Hp7Glu: 13- 1 µM, 
14- 5 µM and 15- 10 µM. Celecoxib (5 µM) was used as positive control 
and inhibited up to 77%. N=3 biological replicates and 1 technical 
measurement, ± SD.    
   Only 6 samples showed positive inhibition and results did not 
replicate previous findings. Q3'SO4 produced around 36% inhibition for 1 
and 5 µM, but provided only 18% during the first test. Indeed, K3Glu at 5 µM 
showed 23% inhibition after the first test, but no inhibition at 5 µM after 
replication. However, K3Glu samples at 1 µM and 10 µM inhibited 17% and 
31% each. Hesperetin conjugates did not show more than 10% COX-2 
inhibition after second assay. This occurrence was unexpected, since they 
provided up to 55% COX-2 inhibition in the first test (see Figure 4.13).  
  Next, ginsenosides (Re, Rh1, Rg1, Rg2 and PPX) were tested and 
only Rg2 (5 µM) and PPX (5 µM) presented around 20% COX-2 inhibition. 
Moreover, results were not consistent with earlier findings.   
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  In the same way, plant extracts were tested to identify any 
concentration dependence and calculate the half maximal inhibitory 
concentration (IC50) for COX-2.  
  Firstly, GT was tested from 10 to 100 µg/mL (see Figure 4.16), 
assuming that at 0.1 mg/mL inhibited 94%. The inhibition at the lowest 
concentration reached more than 35% and quickly increased. Finally, it was 
found that GT inhibited COX-2 in 50% (IC50) at 16.1 µg/mL.    
 
Figure ‎4.16 Percentage of inhibition by GT from 10 to 100 µg/mL. A 
logarithmic equation was obtained and it was calculated IC50 = 16.1 
µg/mL. N=3 biological replicates and 1 technical measurement, ± SD. 
  Additionally, a 1 mg/mL of GT was characterised by Mrs. Hilda 
Nyambe as part of her research project. In brief, GT was characterised using 
a rapid resolution HPLC fitted with a diode array detector, binary pump, 
column and sample thermostat (1200 series Agilent Technologies; Dorset, 
UK). A Zorbax Eclipse Plus-C18 (2.1x100 mm, 1.8 µm) analytical column 
was used to perform the separation and was kept at 35°C. The injection 
volume was 10 µL and the flow rate was set at 0.25 mL/min. Solvent A was 
acidified water (0.1% formic acid, v/v) and solvent B was acetonitrile with 0.1% 
formic acid (v/v). The separation started with 5% solvent B and gradient 
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increase up to 10% B after 5 min. At 20 min the gradient was 40% B and 
reached 90% B at 25 min. This level was kept for 4 min and dropped to 5% 
B after 1 min. The column was re-equilibrated until 33 min.   
  Five major compounds (EGCG, EGC, ECG, EC and caffeine) were 
identified and quantified (see Figure 4.18). Their abundance was calculated 
as follows: EGCG 19.9%, EGC 11.9%, caffeine 5.4%, ECG 3.3% and EC 
2.1%. These results were achieved using commercially-available standards 
and calibration curves for each compound.  
 
Figure ‎4.17 Reverse-phase HPLC analysis of 1 mg/mL of GT powder. In 
order of abundance: EGCG, EGC, caffeine, ECG and EC were identified 
and quantified using commercially available standards. 
Next, based on GT IC50, a theoretical IC50 for the two major 
compounds (EGCG 7 µM and EGC 6.5 µM) was calculated using their 
concentration in GT, and a test was carried out to verify each. At first, EGCG 
was tested using concentrations from 0.5 µM to 32 µM (see Figure 4.19) and 
its IC50 was calculated at 2.8 µM which was lower than the theoretical value 
(7 µM). Following, EGC was tested using the same concentration range from 
EGCG. However, no inhibition was found at 0.5 µM and similar inhibition 
was seen at 1 and 2 µM. Thus, values from 2 µM to 32 µM were used to 
calculate its IC50 which was 9.2 µM (see Figure 4.18). This value was higher 
than the theoretical previously estimated (6.5 µM).  
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Figure ‎4.18 Percentage of inhibition by EGCG and EGC using different 
concentrations. IC50 was 2.8 µM and 9.2 µM respectively. N=2 biological 
replicates and 1 technical measurement, ± SD. 
  Other plant extracts, previously tested, were also analysed. The 
concentrations tested were calculated using as reference the % inhibition 
during first screening. GC was tested from 0.05 to 1 mg/mL and inhibited 
from 12% to 87%. However, the inhibition was not concentration- dependent 
and varied among all concentrations. Cucurbita was tested from 0.025 to 
1.75 mg/mL, and only inhibited at 1.25 and 1.75 mg/mL (4 and 32% 
inhibition respectively). Gingko was tested from 0.01 to 1.50 mg/mL and 
inhibited from 1 to 21%, but it did not show any concentration dependence. 
Indeed, ginseng was tested from 0.01 to 1.75 mg/mL and inhibited from 1 to 
48%, but samples did not show any concentration dependence.  
 Quercetin, hesperetin and Q3'SO4 were selected to be analysed at 
different concentrations. Quercetin was performed from 0.2 to 25 µM and no 
inhibition was observed. Hesperetin was tested from 0.5 to 62.5 µM and it 
showed inhibition from 1 to 19%, but without concentration dependence. 
Finally, Q3'SO4 was performed from 0.2 to 25 µM and inhibited from 3 to 21% 
without concentration dependence manner. A summary of all samples, 
concentration tested and % inhibition can be seen in Table 4.2. 
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Table ‎4.2 Plant extracts and compounds that inhibited recombinant 
human COX-2. The values for GT and its major compounds (EGCG and 
EGC) can be seen in Figure 4.16 and Figure 4.19.  
Plant extract/ 
compound 
Concentration 
(I = mg/mL, 
II = µM) 
PGE2  
(ng/min/µg 
protein) 
SD 
Inhibition 
(%) 
SD 
G
e
rm
a
n
 c
h
a
m
o
m
il
e
 0.05 (I) 46 8.57 12 16.40 
0.075 (I) 44 2.37 15 4.53 
0.1 (I) 47 5.96 11 11.41 
0.25 (I) 31 1.40 41 2.68 
0.5 (I) 25 0.03 52 0.06 
0.75 (I) 29 5.76 44 11.02 
1 (I) 7 2.05 87 3.92 
Cucurbita 
1.25 (I) 43 5.13 4 11.44 
1.75 (I) 30 3.18 32 7.10 
G
in
k
g
o
 
0.05 (I) 30 14.86 21 39.26 
0.1 (I) 37 0.79 1 2.09 
0.25 (I) 36 0.22 4 0.59 
1 (I) 33 4.08 12 10.78 
1.25 (I) 35 8.61 8 22.75 
1.5 (I) 36 0.07 5 0.17 
G
in
s
e
n
g
 
0.01 (I) 34 0.26 1 0.74 
0.025 (I) 33 3.36 4 9.68 
0.05 (I) 33 2.86 4 8.24 
0.25 (I) 34 0.76 1 2.19 
0.5 (1) 20 4.26 41 12.25 
1 (I) 28 0.58 18 1.67 
1.25 (I) 20 1.68 41 4.83 
1.5 (I) 20 0.68 43 1.95 
1.75 (I) 18 4.25 48 12.25 
H
e
s
p
e
re
ti
n
 
0.5 (II) 46 0.32 19 0.55 
1 (II) 57 5.17 1 9.04 
2 (II) 54 4.40 5 7.70 
4 (II) 48 2.57 16 4.49 
10 (II) 48 7.46 15 13.06 
25 (II) 48 6.61 16 11.57 
62.5 (II) 54 5.99 6 10.47 
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Q
3
'S
O
4
 
0.2 (II) 46 3.37 21 5.86 
0.4 (II) 52 5.54 9 9.64 
0.8 (II) 49 1.64 14 2.85 
1.6 (II) 50 1.35 12 2.35 
4 (II) 50 3.03 14 5.28 
10 (II) 49 0.04 14 0.07 
25 (II) 54 0.99 3 1.48 
  
4.6 Discussion 
  Cyclooxygenase 2 (COX-2) is an inducible isoform of COX enzymes 
that it is produced as response of inflammation. COX-2 produces 
inflammatory mediators such as prostaglandin E2 (PGE2) and it has become 
an important target for prevention and treatment of diseases like cancer 
(Srivastava et al., 2009) .  
  Plant extracts are a complex mix of compounds which have attracted 
the attention of research during the last decade. Their use has been strongly 
criticised, as many of their beneficial effects are mainly based on experience 
(Calapai and Caputi, 2007). Therefore, scientific information has become 
fundamental to understand the mechanisms of action and elucidate their 
impact on human beings. 
   Polyphenols are the main bioactive compounds studied in the plant 
extracts and their effects are still under investigation (Cai et al., 2004). The 
methodologies to test these compounds are diverse and provide different 
types of results which need to be analysed carefully to avoid discrepancy in 
the conclusions. Animal and cell culture studies are the most common 
assays used in research. For example, Maruyama et al. (2010) tested the 
anti-inflammatory activity of bee pollen from Cistus sp. (Spanish origin) using 
a carrageen-induced paw edema in rats. They described their results in % 
swelling and found that bee pollen and the fraction extracted with ethanol 
showed up to 73% less swelling (ethanol fraction). They characterised the 
ethanol fraction using NMR and found kaempferol glucoside, quercetin 
rhamnoside, quercetin, kaempferol and isoharmentin as main components, 
but quantification and experiments with individual compounds were not 
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performed. Gautam et al. (2011),tested anti-inflammatory properties of Ajuga 
bracteosa in mice using the TPA-induced mouse ear edema assay. They 
used a 70% ethanol-extracted fraction and compared two doses. As it was 
expected, the higher concentration inhibited up to 70% more compared with 
the control. They isolated five compounds, but none was used in this assay. 
Even though animal models are widely used to test drugs and plant extracts, 
they do not provide the complete information about how these compounds 
work (Webb, 2014). For example, carrageen-induced paw edema is tipically 
used as a model of inflammation, but it presents information about 
generalised inflammation and it is not specific of any mechanism (Whiteley 
and Dalrymple, 2001; Webb, 2014). Cell culture studies, using different 
sources and types of cells, have also contributed to understand how plant 
extracts/polyphenols function against pro-inflammatory enzymes (Peng et al., 
2006; Yang et al., 2011). However, differences in cell lines and different 
inflammatory responses have an impact on results which can lead to 
inconsistent outcomes (Lotito et al., 2011). Another way to undertake this 
challenge it is through in vitro assays. We compared two types of 
methodologies to measure the inhibition of COX-2 by plant extracts and their 
main components as conjugated or unconjugated polyphenols.  
  Firstly, a COX inhibition assay was used to test a wide range of 
polyphenols and various plant extracts. The assay was performed following 
the manufacturer’s instructions, but the reproducibility was not consistent. To 
ensure that the recombinant human COX-2 worked and the procedure was 
followed correctly, celecoxib (5 µM) was used as positive control. Different 
dilutions were tested to examine if the binding response of PGE2 during the 
immunoassay was affected by the dilution factor. No pattern was found and 
high variations in the results were seen. For example, ginsenoside Re (5 µM) 
was tested at different dilution factors (100x, 200x and 250x) and it showed 
25%, 14% and 45% inhibition respectively, but celecoxib (5 µM) showed 
consistently more than 80% inhibition. In fact, distinct inhibition could be only 
seen for the plant extracts (see Figure 4.4) were GT and GC provided more 
than 75% inhibition. These results were used to perform further experiments. 
However, other researches have used this methodology to support their 
findings. Cheong et al. (2004), used the same in vitro assay to test different 
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concentrations of quercetin (1, 10, 50, 100 and 1000 µM) and compared 
them to resveratrol (30 µM) and NS-398 (10 µM). They did not provide any % 
inhibition and their graphic results are not comparable with our findings. Also, 
the procedure to analyse their results is not reported.  Maruyama et al. 
(2010), performed the COX inhibitor screening assay testing bee pollen 
extracts at different concentrations. They did not report the use of a 
positive/negative control and their results were analysed by linear regression. 
No single compounds were tested. Finally, Gautam et al. (2011) also used 
the same in vitro assay for Ajuga bracteosa to test inhibition of COX-1 and 
COX-2. They analysed two different concentrations (25 and 50 µg/mL) and 
celecoxib at 30 µM, but none specific polyphenols were reported. The 
method to analyse their results was not reported. Overall, the COX inhibitor 
screening assay is a good method to determine if a plant extract has any 
inhibitory activity against COX-2, but it will not provide explicit information 
about the activity of its polyphenol content. Indeed, it is important to address 
that any data produced using this in vitro assay should be analysed using a 
4-parameter analysis, as ligand binding assays are usually  characterised by 
a sigmodial relationship between the mean response and the compound 
concentration (Findlay and Dillard, 2007).  
  A different strategy to establish if an analyte inhibits COX-2 it is 
through the combination of an in vitro assay and the measurement of PGE2 
by mass spectrometry. The methodology for the in vitro assay has been 
reported by Cao et al. (2010; 2011) and recently by Zhu et al. (2014) and 
Deng et al. (2014) who compared derivatization and magnetic ligand fishing 
of PGE2 to the original protocol. The in vitro assay performed during our 
analysis used Tris-HCl buffer as negative control instead of DMSO. The 
quantification of PGE2 produced after recombinant human COX-2 inhibition 
was carried out using the protocol published by Cao et al. (2011) using a LC-
ESI/MS instead of a LC-ESI/MS2. The LOD and LOQ calculated for PGE2 
during our quantification (see 4.5.2)  were not as good as those previously 
reported by Cao et al. (2011) (LOD=0.2 pg, LOQ=1 pg) and Zhu et al. (2014) 
(LOD=0.006 pg, LOQ=0.0255 pg) who used a gradient protocol to perform 
the measurement of PGE2. The variation could be due to the specificity of 
the LC-MS2 which at lower concentrations provides higher signal in 
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comparison with LC-MS. None of the previous authors provided LOD and 
LOQ for the surrogate d4-PGE2.  
  Inhibition of recombinant human COX-2 by aglycones and conjugated 
polyphenols was not reproducible, as it showed inconsistent results after 
various repetitions, except for EGC and EGCG. The measurement of PGE2 
by mass spectrometry is one of the latest methodologies to detect 
prostaglandins in biological samples, and methodologies already published 
have only used LC-ESI/MS2, but not LC-ESI/MS. During the LC-ESI/MS 
analysis, a standard curve for the surrogate was performed (data not shown) 
to determine the amount of d4-PGE2 remaining after liquid-liquid extraction. 
However, it was found that the absolute intensity (MS signal) was enhanced 
after the solvent extraction; then, the absolute intensity from a sample 
without inhibitor, but with a known amount of surrogate (0.43 ng) was used 
to correct for losses (see 4.5.2). This phenomenon might suggest that the 
sample mixture and the solvent extraction interfere with the evaluation of 
PGE2 which could have led to instability of the measurement. Other organic 
solvents have been used to extract PGE2 from biological samples (Brose et 
al., 2011) which could improve the reproducibility of results. Even though 
results did not agree for most of the polyphenols and plant extracts tested, 
green tea and its two major polyphenols (EGCG and EGC) showed 
consistent inhibition. This could also suggest that the in vitro assay is 
affected by the type of polyphenol or plant extract to test, as different 
subclasses of polyphenols were analysed. For instance, EGCG and EGC 
are considered catechins and belong to the subclass flavanol, and quercetin 
and kaempferol are flavonols. On the other hand, the inhibition by plant 
extracts provided enough evidence to support previous reports suggesting 
that GT inhibits recombinant human COX-2. Lately, Deng et al. (2014) have 
reported the analysis of a variety of green tea (Yunwu, Camellia sinensis) 
obtained from the Tea Research Institute of Hunan province in China. They 
performed a modified protocol by Cao et al. (2011) and compared it to a new 
screening assay based on magnetic ligand fishing. Their IC50 for green tea 
was 437.3 µg/mL which is 27x more than our reported value (16.1 µg/mL) 
and it suggests that our green tea was richer in polyphenols (COX-2 
inhibitors) than their sample. They performed the in vitro assay testing the 
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main polyphenols of green tea, but only reported IC50 for 3''-O-methyl-EGCG 
= 0.17 µM and 3''-O-methyl-ECG = 0.16 µM which were not tested by us. 
Publications about GT mostly report inhibition of COX-2 expression in cell 
lines models. For instance, Peng et al. (2006) cultured HT-27 and HCA-7 
cells with various concentrations of EGCG (from 10 µM to 300 µM) and 
incubated them for 48 hrs. Next, they performed a series of different 
experiments which showed that EGCG inhibited the expression of COX-2 
protein and mRNA in both cell lines. Western blot analysis showed that at 
200 µM EGCG treatment, COX-2 protein expression was inhibited by 57% in 
HT-29 and 44% in HCA-7. Also, they found that COX-2 protein expression 
decreased due to reduction in COX-2 mRNA expression. Indeed, they 
showed that EGCG cut down COX-2 promoter activity in a dose-dependant 
manner and located the transcription factor NF-κB as the regulator of COX-2 
expression. Recently, Singh and Katiyar (2011) also used cell lines to 
assess the inhibitory activity of EGCG in human melanoma cells. They used 
normal epidermal melanocytes and human melanoma cell lines (A375 and 
Hs294t) to perform their experiments. They found a reduction of endogenous 
expression of COX-2 in cell lysates (A375 and Hs294t lines) by Western blot 
analysis which was reduced in a concentration-dependant manner. They 
quantified the production of PGE2 by the same immunoassay that we used 
to test COX-2 inhibition. However, their analysis involved melanoma cell 
homogenates and not single compounds. They treated A375 cells with 
various concentrations of EGCG (10,20 and 40 µg/mL) for 24 hrs and 
revealed that EGCG decreased the translocation of NF-κB/p65 into the 
nucleus in a dose-dependant pattern. Both publications agreed that EGCG 
modulates NF-κB and this information provides a key target to approach in 
anti-inflammatory and anti-cancer therapies. 
  Altogether, this is the first attempt to screen a series of different 
polyphenols and plant extracts for their recombinant human COX-2 inhibition 
activity using two different techniques (spectrophotometer and mass 
spectrometry). These analytes presented a wide range of characteristics and 
chemical structures which might have had impact on their response in both 
methodologies. Certainly, there is still a lack of information of COX-2 
inhibition by GT and its two major compounds (EGCG and EGC), tested as 
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single compounds, in the literature. Although the mass spectrometry 
methodology is similar to other methods already reported, this assay 
provides a faster analysis than ELISA and it does not involve the use of 
derivatization or immobilization of COX-2 which could potentially minimise 
sample handling. 
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CHAPTER 5  Summary and Future Perspectives  
 
5.1 Outcomes 
  Plant extracts and their constituent polyphenols have become an 
important research subject in recent years and their use in Western society 
is growing (Bodeker and Kronenberg, 2002). Different techniques have been 
used to identify and quantify the polyphenol content of plant extracts and 
determine their beneficial effect on human beings. The work here presented 
has focused in the impact of human metabolism on the polyphenols in the 
plant extracts. Mass spectrometry measurements and in vitro assays have 
been used to provide more information about the metabolism and activity of 
these compounds.  
  The first step of metabolism is characterised by the enzymatic 
cleavage of sugars, and it is most likely to occur in the gastrointestinal tract 
or in the food itself (Scalbert and Williamson, 2000). This step was mimicked 
using enzymatic hydrolysis on GC by a method using multiple-enzyme 
hydrolysis (hesperidinase and cellulase) (Chapter 2). This approach was 
previously tested in five different fruit matrices and demonstrated potential 
versatility for other plant based materials (Pimpão et al., 2013). The 
methodology helped to simplify the identification of the main polyphenols in 
GC (see Figure 2.2, 2.4-2.5) which can be possibly applied to other plant 
extracts. The main polyphenol in GC is known to be apigenin-7-O-glucoside 
and publications have paid more attention to its quantification and 
identification of its by-product. Consequently, the identification and 
quantification of other polyphenols using true standards was our goal. Our 
results agreed with previous reports identifying various polyphenols in GC 
(see Table 2.2). The quantification of eight compounds (see Table 2.3) 
suggested that the variation in the origin of the plant extract and the use of 
different preparation methods cause high dissimilarity in the quantification of 
these compounds (Novakova et al., 2010; Raal et al., 2012; Guimarães et al., 
2013). Indeed, the specificity of the equipment (LC-MS2, LC-MS or HPLC) 
had an impact in the identification and quantification of small quantities of 
polyphenol present in the plant, increasing with the complexity of the 
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analytical tool (Novakova et al., 2010). Additionally, the deproteinization and 
extraction using acetonitrile showed higher recovery of aglycones after 
hydrolysis, but it was not as effective as expected. The concentration of the 
main GC aglycones (apigenin and luteolin) did not increase after hydrolysis 
which suggested that non-hydrolysed glucosides were lost during the solvent 
extraction. Glucosides are more water-soluble than their aglycones and their 
concentration might have been underestimated. Therefore, it is recommend 
that after enzymatic hydrolysis a liquid-liquid extraction should be carried out 
with other organic solvents miscible in water such as 2-propanol or ethanol. 
Methanol is not recommended as it can promote spontaneous methylation 
and deliver incorrect results (Xie et al., 1993). Overall, the combined use of 
LC-ESI/MS2 and LC-ESI/MS helped to identify with more accuracy those 
compounds with scientific interest and decreased the time of analysis.  
   After the first step of metabolism, a second series of reactions occurs 
and analytes are known as phase II metabolites. Polyphenols are 
conjugated into different metabolites to be further excreted through biological 
fluids (e.g. blood, urine). Urinary metabolites are usually investigated, as 
urine collection is not invasive and samples can be gathered by the subject. 
Moreover, for the second part of the project, the main targets were to sulfate 
hesperetin, identifty its main sulfated form and identify/quantify its main 
metabolites in human samples (urine) after orange juice consumption 
(Chapter 3). The first goal was established after various publications 
reported a lack of enzymatic hydrolysis for different polyphenols (e.g. 
epicatechin) using β-glucuronidase and sulfatase and which could potentially 
lead to flaw results (Vallejo et al., 2010; Saha et al., 2012; Charoensuk, 
2014). Enzymatic hydrolysis is commonly used to identify and quantify 
urinary metabolites without the need of true standards. The methodology 
here reported introduced a new co-cofactor (p-nitrophenyl sulfate, PNS) 
which increased the transformation of hesperetin to hesperetin sulfate 
(Hp3'SO4) up to 80% and its mechanism of action can be seen in Figure 
3.13. The positive identification and quantification of Hp3'SO4 by LC-ESI/MS 
provided enough information to quantify the main urinary hesperetin 
metabolites after orange juice ingestion. Samples from a cross-over human 
study were collected and analysed by Dr. Tristan P. Dew and Miss Isabella 
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Procopiou using true standards for identification and quantification of 
hesperetin metabolites. Then, the data was assessed, statistically analysed 
and interpreted by this researcher. Three commercial orange juices were 
used during the study and their main metabolites were quantified by LC-
ESI/MS. It was found that the MS response (absolute intensity) from 
Hp3'SO4 was 2.3x higher than its aglycone and this factor was used to 
correct the urine measurements for Hp3'SO4 (see section 3.5.3.2). This 
phenomenon has been also detected in measurements by LC-ESI/MS2 and 
HPLC-DAD using hydroxycinnamic acid conjugates and hesperetin sulfate 
(Brand et al., 2010; Farrell et al., 2011), but it was not reported in the latest 
measurement of hesperetin metabolites (Pereira-Caro et al., 2014). The 
statistical analysis of the data showed a statistically significant difference 
between the freshly squeezed orange juice and value brand orange juice 
(see Figure 3.10) where the total metabolites excretion was 7% higher in 
freshly squeezed than the value brand. Statistically significant differences for 
each metabolite excretion were found between freshly squeezed and value 
brand orange juices. The concentration of Hp7Glu was 1% higher in freshly 
squeezed than the value brand. As well, Hp3'Glu was 5.6% higher in freshly 
squeezed than the value brand. Finally, Hp3'SO4 was 0.8% higher in freshly 
squeezed than the value brand. A concise report of the measured values 
and those reported in the literature can be seen in Table 3.3 and 3.4. The 
considerable difference seen in Hp3'Glu could be explained due to the 
variability among the subjects, as two outliers were identified for this 
metabolite. It has been proposed that the excretion of these metabolites is 
affected by the gut microflora (Erlund et al., 2001). Therefore, these inter-
individual variations might suggest that the specific enzymatic activity of the 
colonic microflora in each participant plays an important role in the 
metabolism of flavonoids (Manach et al., 2003; Pereira-Caro et al., 2014). 
On the other hand, Bredsdorff et al. (2010) suggested that hesperetin and 
naringenin are glucuronidated/sulfated in the same pattern without being 
affected by the site of absorption. They concluded that the metabolism of 
these two polyphenols after absorption in the small intestine was not 
significantly different from the metabolism after absorption in the colon. Then, 
it is advised that further quantification of urinary-hesperetin metabolites are 
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designed studies using a large pool of participants which could potentially 
decrease the effects of the inter-individual variations. Indeed, it is 
recommended to pay attention to the MS response of polyphenol 
metabolites to avoid inaccurate measurements in future experiments. 
  After the plant extracts were characterised and their main polyphenols 
identified, the next step was to investigate their potential health benefit. Our 
target was the anti-inflammatory activity of these compounds and we 
focused in the inhibitory activity against cyclooxygenase 2 (COX-2). This 
pro-inflammatory enzyme has been related to arthritis and various types of 
cancer (Raman et al., 2008). Selective inhibitors have been previously 
developed, but recent studies have found an association of their intake with 
an increase in blood pressure which leads to myocardial infarction or stroke 
(Raman et al., 2008; Salvado et al., 2012). Consequently, scientists are 
seeking for harmless alternatives to inhibit effectively COX-2 and avoid or 
provide fewer side effects. For that reason, the third experimental part 
focused on cell-free models to screen plant extracts and their main 
aglycones and conjugate polyphenols (Chapter 4).  A COX inhibitor 
screening assay was used to quantify directly PGF2α via enzyme 
immunoassay (EIA) (see Figures 4.1 and 4.2) and various plant extracts and 
their main aglycone/conjugated polyphenols were tested. It was found that 
the screening assay provided sufficient information to determine if the 
sample was or was not an inhibitor of COX-2, but it did not give reproducible 
results if concentration dependence was sought for. In this case, different 
dilutions were tested to investigate if the amount of PGF2α binding in the EIA 
was affected by the dilution factor. The positive control (celecoxib) showed 
consistently more than 80% inhibition, but samples (e.g. ginsenoside Re) did 
not give any inhibition. Only plant extracts (GT and GC) provided more than 
75% inhibition and they were further analysed by our second methodology. 
Recently, published reports using this in vitro assay testing natural materials 
(bee pollen, Ajuga bracteosa) and quercetin reported concentration 
dependence for their samples tested (Cheong et al., 2004; Maruyama et al., 
2010; Gautam et al., 2011). Even though their samples were compared with 
positive controls (resveratrol, NS-398 and celecoxib), they used these 
inhibitors at higher concentrations (resveratrol-30 µM, NS-398-10 µM and 
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celecoxib-30 µM) than our experiment (5 µM). In addition, only Maruyama et 
al. (2010) reported their method of data analysis (linear regression) which it 
is not the most recommended method to analyse ligand binding assays. The 
4-parameter analysis was used to analyse our results from the in vitro assay 
by recommendation of the manufacturer and taking into account that data 
from ligand binding assays is usually characterised by a sigmodial 
relationship between the mean response and the compound concentration 
(Findlay and Dillard, 2007). We found that the COX inhibitor screening assay 
is a useful test to evaluate the inhibitory activity of plant extracts and 
polyphenols, but it is recommended to be used in combination with other 
techniques to assure their results. As a result, another approach was applied 
to calculate the inhibitory activity of COX-2. An integrated methodology using 
an in vitro assay and PGE2 measurement by LC-ESI/MS was performed. 
This methodology is a novel approach to determine if plant extracts and their 
main polyphenols have inhibitory activity. It was firstly reported using various 
nonsteroidal anti-inflammatory drugs (celecoxib, indomethacin and 
diclofenac) and resveratrol, but it has been extended to other compounds 
(e.g. EGCG) and plant extracts (e.g. green tea, Chinese herbs) (Cao et al., 
2011; Zhu et al., 2014; Deng et al., 2014). Inhibition of recombinant human 
COX-2 by aglycones/conjugated polyphenols was not consistent and results 
could not been replicated throughout various repetitions. During the first 
stage of the optimisation, it was found that after liquid-liquid extraction the 
absolute intensity (MS signal) of the surrogate d4-PGE2 was enhanced. This 
anomaly might suggest that the sample composition and the solvent 
extraction interfere with the evaluation of PGE2 which could affect the 
measurement. For further experimentation, it is advised to test different 
organic solvents to extract PGE2 (e.g. acetone) and spike controls with 
sample mix after the reaction has ended to tackle any effect by sample 
composition. Our experiments using EGCG and EGC showed consistent 
inhibition that could indicate that the in vitro assay is affected by the type of 
polyphenol or plant extract to test, as different polyphenols were analysed. 
For example, flavonols (quercetin and kaempferol), flavanols (EGCG and 
EGC) and flavanones (hesperetin) and ginsenosides were used to perform 
the assay. In contrast, the inhibition by plant extracts provided enough 
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evidence to support previous reports suggesting that GT inhibits 
recombinant human COX-2. The last publication using mass spectrometry to 
test the inhibition of COX-2 by green tea and its major polyphenols (Deng et 
al., 2014) reported a greater IC50 for green tea (437.3 µg/mL) than our 
reported value (16.1 µg/mL) and they did not report any IC50 for EGCG or 
EGC. Other publications testing GT and its main polyphenols have mainly 
looked into inhibition of COX-2 expression using different cell line models 
(Peng et al., 2006; Singh and Katiyar, 2011) and they have agreed that 
EGCG modulates NF-κB and reduces COX-2 mRNA expression in a dose-
dependant pattern. Overall, mass spectrometry could be used as a routinely 
methodology to quantify PGE2, but different parameters such as solvent 
extraction, sample composition and chemical structure of the analyte should 
be further investigated. This methodology could provide faster analysis than 
ELISA and could also minimise sample handling procedures.  
 
5.2 Future work 
5.2.1 5-Lipoxygenase and the methods to quantify its inhibition.  
   Besides prostaglandin-endoperoxide synthase 2 that catalyses the 
first step of arachidonic acid pathway (see Figure 4.1), there is another 
family of enzymes in mammalian cells that are lipid mediators derived from 
oxidative modification of arachidonic acid. Lipoxygenase enzymes have 
been related to inflammatory and immunomodulatory functions in disease, 
as well as homeostatic effects in normal processes (Griesser et al., 2011). 5-
Lipooxygenase (5-LOX) is the main enzyme controlling the synthesis of 
leukotrienes (LTs) and hydroxyeicosatetroenoic acid (HETE) from 
arachidonic acid (see Figure 5.1) (Willey et al., 2008). The products of 5-
LOX have been related to certain disorders such as asthma, osteoporosis, 
cancer (e.g. prostate, breast) and cardiovascular diseases as 
artherosclerosis and stroke (Werz, 2007).  
  Numerous metabolites can be examined to determine the activity of 
5-LOX. For example, 5-HETE is typically measured due to its stability and 
removes the possibility of interference due to additional enzymes (e.g. LTA4 
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hydrolase) (Willey et al., 2008). Researches have focused their efforts 
towards two types of systems: cell models and cell-free assays. 
 
Figure ‎5.1 Conversion of arachidonic acid by 5-lipoxygenase. 5-HPETE: 
5-hydroperoxyeicosatetraeinoic acid, 5-HETE: 5-
hydroxyeicosatetraenoic acid, FLAP: 5-lipoxygenase activating protein, 
LTA4: leukotriene A4 and LTB4: leukotriene B4.  
  Cell-free models have been developed to be simpler and rapid assays 
which could decrease the time of analysis and contribute to the 
understanding of 5-LOX inhibitors. For instance, Lu et al. (2013) have 
proposed a colorimetric assay to indirectly measure 5-LOX activity using the 
ferric thiocyanate (FTC) method. Once the LOX-derived lipid peroxidases 
have been produced, they oxidise the ferrous ion (Fe2+) to the ferric ion (Fe3+) 
which binds with thiocyanate (SCN-) and generates the red ferrithiocyanate 
(FTC) complex. In brief, the method is performed as follows:  95 µL of assay 
buffer (Tris-HCl, 50 mM, pH 7.5) is added to wells (96-well plate) in 
combination with recombinant human LOX. Then, 5 µL of arachidonic acid 
solution (2 mM) is added and the mixture is incubated for 6 min at room 
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temperature. The reagent FTC is added (100 µL) to terminate the reaction 
and after 5 min the absorbance is measured at 480 nm. If an inhibitor is 
used, the compound is incubated with the enzyme for 5 min before the 
addition of arachidonic acid. They found that the colour development was 
LOX and arachidonic dependant. Also, the absorbance of the background 
was consistently low if arachidonic acid and FTC reagent were prepared 
freshly. The limit of detection was determined at 0.5 nM.  
  We performed a preliminary test using recombinant human LOX and 
two known LOX inhibitors (fisetin and quercetin). The results can be seen in 
Figure 5.2. 
 
Figure ‎5.2 Absorbance values for different samples using the FTC 
complex method. 1- Blank1 (no LOX, no inhibitor), 2- Blank2 (no LOX), 
3-100% activity, 4- Positive control (fisetin, 5 µM), 5- Quercetin, 5 µM. 
N= 2 biological replicates and 1 technical measurement.  
   The inhibition by fisetin or quercetin was not clear. Then, 5-LOX was 
compared to lipoxygenase from soybean which is used in other in vitro 
assays to determine the inhibitory activity of polyphenols (Chedea and 
Jisaka, 2011). We also measured the absorbance at three time points 5, 10 
and 15 min. Results can be seen in Figure 5.3.  
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Figure ‎5.3 Comparison between human arachidonate-5-lipoxygenase 
(Human, 5-LOX) and lipoxygenase from soybean (Soybean). The 
Roman numberals represent the time point of measurement in min; e.g. 
V = 5 min. Fisetin and quercetin were tested at 5 µM. N=2 biological 
replicates and 1 technical measurement.  
  It was expected to obtain higher inhibition, as the IC50 for quercetin 
and fisetin reported by Lu et al. (2013) were 1.8 and 1.2 µM respectively. 
Further, it was noticed that absorbance values were too low for 5-LOX in 
comparison with lipoxygenase from soybean. This could suggest that the 
assay has a limited working range and it might represent an important 
restriction to take into account for further experiments. Even though the 
assay allows to process different compounds at the same time, it does not 
simplifies reagent preparation which could affect the replication of results. 
  Alternative approaches to identify and quantify the inhibition of 5-LOX 
have involved in vitro assays and mass spectrometry (Kanamoto et al., 2009) 
which is similar to our rationale to measure the activity of recombinant 
human COX-2. Schewe et al. (2002), reported the inhibition of 5-LOX by the 
main polyphenols from cocoa. Their protocol uses aliquots of lysate 
supernatant mixed with Tris buffer (50 mM, pH 7.4) and pre-incubation for 10 
min in the presence/absence of the polyphenol. Then, an assay mixture 
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containing ATP (1 mM), CaCl2 (4 mM), EDTA (1 mM) and dipalmitoyl 
phosphatidylcholine (13 mg/L) is added. After 5 min more, the reaction is 
initiated by the addition of arachidonic acid (33 mM) in methanol and the 
reaction is stopped after 15 min by the addition of cold methanol. Their 
samples are treated with sodium borohydride and glacial acetic acid which 
later are centrifuged (5 min, 4 000 g) and directly used for HPLC analysis. In 
a similar way, Mohamed et al. (2014) reported the inhibition of 5-LOX by 
ascorbic acid 6-palmitate. They modified the method by Aharony and Stein 
(1986) that uses phosphate buffer (100 mM, pH 7.4), DTT (50 µM), ATP 
(200 µM), CaCl2 (300 µM), arachidonic acid and enzyme (5 µg protein). Both 
protocols do not use any internal standard to correct losses by sample 
handling, so the surrogate d8-5-HETE can be used for this purpose. 
  Furthermore, the appropriate method of detection is equally important. 
Various publications have reported the detection and measurement of 
different arachidonic acid metabolites, including 5-HETE. For instance, 
Kempen et al. (2001) measured various arachidonic metabolites (e.g. 5-
HETE) in cultured tumour cells using LC-ESI/MS2 applying a gradient 
protocol, ammonium acetate and methanol as mobile phases and a 
hydrophilic C18 column to perform the analysis. Zick et al. (2011), employed 
a LC-ESI/MS2 to test ginger and its inhibitory effect in the production of 
eicosanoids in the colonic mucosa of healthy volunteers. The eicosanoid 
levels were measured by a linear methanol gradient and a phenyl-hexyl 
chromatographic column. Then, Yue et al. (2007) developed a method in 
LC-ESI/MS to measure simultaneously arachidonic acid and eicosanoids 
from cyclooxygenase and lipoxygenase pathways in rat brain tissue. They 
used a gradient protocol, acidified water and acetonitrile with formic acid as 
mobile phases and a C18 column for the separation. Finally, Blewett et al. 
(2008) developed a method utilising LC-ESI/MS to separate and quantify 23 
different eicosanoids and their method was applied to rat kidney tissue. They 
employed a gradient protocol, acidified water and acetonitrile with formic 
acid as mobile phases and a C18 column for the separation. Once this 
information was gathered, we performed a preliminary identification of 5-
HETE and its surrogate d8-5-HETE to establish the suitable conditions for 
our LC-ESI/MS equipment. First, we modified the method by Blewett et al. 
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(2008). In brief, a Waters XTerra MS C18 column was used to perform the 
separation and it was kept at 40°C. The mobile phase A consisted of 
acidified water (0.1% formic acid, v/v) and mobile phase B of acetonitrile with 
0.1% formic acid (v/v). The flow rate was set at 0.150 mL/min. The gradient 
elution started at 40% B and it was kept for 1.4 min. Then, solvent B 
increased up to 65% at 3.5 min and it was hold up to 5.6 min. Solvent B 
raised to 90% at 6.3 min and it was hold up to 7.7 min. Finally, the column 
re-equilibrated to 40% from 7.7 to 8.5 min. The injection volume was 2 µL. 
The chromatography obtained from this test can be seen in Figure 5.4  
 
Figure ‎5.4 MS chromatography for the total ion counting (TIC) for 0.5 
µM 5-HETE and 5 µM d8-5-HETE. 
  The standards were measured at two different concentrations: 0.5 µM 
for 5-HETE and 5 µM for d8-5-HETE, as we wanted to test if 10x higher 
concentration will show 10x more absolute intensity. The result agreed with 
our rationale. Next, we measured both standards at a lower concentration 
(100 nM). The MS chromatography can be seen in Figure 5.5. 
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Figure ‎5.5 Total ion counting (TIC) for 5-HETE and d8-5-HETE. Both 
standards were measured at 100 nM.  
  It was noticed that the chromatography was less clear than the first 
attempt which could suggest that background noise will interfere with the 
accurate measurement of each metabolite. At last, an in vitro assay was 
performed following a modified method by Mohamed et al. (2014). A mixture 
containing phosphate buffer (100 mM, pH 7.4), DTT (50 µM), ATP (200 µM) 
and CaCl2 (300 µM) was pre-incubated with 5-LOX (0.1 µg) and the inhibitor 
zileuton (5 µM) for 2 min at room temperature. Then, arachidonic acid (150 
µM) was added and 5 min later the reaction was stopped with HCl (6N). The 
surrogate, d8-5-HETE was added (100 nM) and the mixture solution was 
extracted twice with diethyl ether:hexane (50:50, v/v). The combined 
supernatants were dried under a N2 stream and reconstituted with 
methanol:water (50:50, v/v) prior to LC-MS analysis. Remaining samples 
were kept at -20°C. Even though the target metabolites, 5-HETE and d8-5-
HETE were visible, the chromatography was more instable than previous 
tests (see Figure 5.6).  
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Figure ‎5.6 Total ion counting (TIC) and negative mass-to-charge ratio 
(m/z) for three different samples and each sought metabolite (319:5-
HETE, 327:d8-5-HETE) . A- blank, no enzyme (5-LOX) and no inhibitor, 
B- 100% activity, no inhibitor and C- zileuton (5µM). 
  Overall, the in vitro assay and mass spectrometry methodologies 
require a systematic-method development which could provide with a new 
validated method to identify and quantify the inhibitory activity of 5-LOX of 
plant based materials and their main polyphenols. 
5.2.2 Plant extracts and future research 
  Plant extracts and plant-derived compounds are highly sought by the 
Western society as an alternative to prevent or treat diseases. Although 
some of the effects and doses have been suggested by the Traditional 
Medicine, there is still a lack of scientific background that validates this 
knowledge. The results reported in this thesis have shown that plant extracts, 
after ingestion, undergo a series of transformations which lead to a change 
in their biological activity. These effects would need to be deeply 
investigated and, in the future, tested in clinical trials.  
  Further research in plant extracts should show the composition of the 
plant first, then look for its changes after ingestion and finally establish a 
profile of the possible compounds to be metabolised. It is important to pay 
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attention of the type of compounds found (chemical structures) as their 
differences can determine their possible behaviour. Indeed, conjugated 
metabolites should be synthesised to confirm their occurrence after human 
ingestion which could be used in in vitro assays to test the possible 
interactions with target analytes, such as pro-inflammatory enzymes.  
  It is important to address that quantification of conjugated metabolites 
using enzymatic deconjugation should be used carefully or, if it is possible, 
to be avoided as it could lead to incorrect measurements. Analysis of these 
metabolites in biological samples (urine/blood) and concentration-
dependence interventions should be targets in future work on plant extracts.  
  The information already documented about the possible effects of the 
plant extracts should be taken into account to evaluate the biological activity 
of the extract and its metabolites. For example, our research focused on pro-
inflammatory enzymes as different publications suggested the positive 
effects of the plant extracts against inflammation. Certainly, these effects 
can be measured by different techniques such as animal models, cell 
models or cell-free assays which could be used independently or combined. 
In addition, equipment that is already used in pharmacokinetics as HPLC or 
LC-MS can help to minimise the time of analysis and reduce the cost of the 
investigation. It is also necessary to detect the toxic dose of the plant 
extracts to prevent any adverse effects. Overall, all this data could promote 
or dismiss the use of plant extracts in the future.  
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